id
stringlengths
22
37
tokens
sequence
ner_tags
sequence
texts
stringlengths
0
39.2k
1619718-04-Results-p01
[ "KRAS", "mutation", "occurred", "in", "26.5%", "and", "BRAF", "mutation", "in", "4.8%", "of", "adenomas", "(all", "types)", "(Table", "1)", "(P", "<", "0.0001).", "TVAs/VAs", "were", "more", "likely", "to", "have", "KRAS", "mutation", "(50%)", "than", "TAs", "<", " ", "10", "mm", "(18%)", "(P", "<", "0.004)", "or", "TAS", ">", " ", "10", "mm", "in", "diameter", "(17%)", "(P", "<", "0.02).", "In", "the", "case", "of", "TAs", "there", "was", "a", "trend", "for", "KRAS", "mutation", "to", "occur", "more", "frequently", "in", "polyps", "from", "the", "proximal", "colon", "(P", "=", "0.08)", "and", "in", "females", "(P", "=", "0.07)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
KRAS mutation occurred in 26.5% and BRAF mutation in 4.8% of adenomas (all types) (Table 1) (P < 0.0001). TVAs/VAs were more likely to have KRAS mutation (50%) than TAs <   10 mm (18%) (P < 0.004) or TAS >   10 mm in diameter (17%) (P < 0.02). In the case of TAs there was a trend for KRAS mutation to occur more frequently in polyps from the proximal colon (P = 0.08) and in females (P = 0.07).
1334229-03-Methods-p01
[ "The", "PALGA", "reports", "were", "used", "to", "identify", "and", "locate", "tumour", "tissue", "from", "eligible", "colorectal", "cancer", "patients", "in", "Dutch", "pathology", "laboratories.", "Colon", "and", "rectal", "cancer", "were", "classified", "according", "to", "site", "as", "follows,", "colon:", "cecum", "through", "sigmoid", "colon", "(ICD-O", "codes", "153.0,", "153.1,", "153.2,", "153.3,", "153.4,", "153.5,", "153.6,", "153.7),", "rectosigmoid", " ", "(ICD-O", "code", "154.0),", "and", "rectum", "(ICD-O", "code", "154.1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The PALGA reports were used to identify and locate tumour tissue from eligible colorectal cancer patients in Dutch pathology laboratories. Colon and rectal cancer were classified according to site as follows, colon: cecum through sigmoid colon (ICD-O codes 153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7), rectosigmoid (ICD-O code 154.0), and rectum (ICD-O code 154.1).
2275286-01-Abstract-p01
[ "Results" ]
[ 0 ]
Results
3034663-04-Results-p01
[ "In", "one", "of", "the", "families", "with", "LS,", "the", "index", "subject", "was", "heterozygous", "for", "a", "pathogenic", "MLH1", "variant", "(c.767C>T;", "p.Arg226X)", "and", "the", "p.Lys618Ala", "variant.", "Two", "of", "his", "offspring,", "who", "were", "diagnosed", "with", "CRC", "at", "the", "ages", "of", "36", "and", "39", "years,", "carried", "the", "deleterious", "variant", "but", "not", "the", "p.Lys618Ala", "variant.", "An", "unaffected", "daughter", "(III-12)", "carried", "the", "p.Lys618Ala", " ", "variant", "but", "not", "the", "deleterious", "variant.", "Two", "nephews", "11", " ", "were", "controls", "(11/411,", "2.68%),", "nine", "were", "CRC", "patients", "from", "the", "sporadic", "group", "(9/373,", "2.41%)", "and", "seven", "were", "CRC", "patients", "from", "the", "familial", "group", "(7/250,", "2.8%).", "None", "of", "the", "individuals", "was", "homozygous", "for", "the", "minor", "allele." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 0, 0, 0, 0, 0, 0, 0, 0, 13, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In one of the families with LS, the index subject was heterozygous for a pathogenic MLH1 variant (c.767C>T; p.Arg226X) and the p.Lys618Ala variant. Two of his offspring, who were diagnosed with CRC at the ages of 36 and 39 years, carried the deleterious variant but not the p.Lys618Ala variant. An unaffected daughter (III-12) carried the p.Lys618Ala variant but not the deleterious variant. Two nephews 11 were controls (11/411, 2.68%), nine were CRC patients from the sporadic group (9/373, 2.41%) and seven were CRC patients from the familial group (7/250, 2.8%). None of the individuals was homozygous for the minor allele.
3034663-03-Methods-p01
[ "No", "familial", "history", "of", "cancer", "was", "available", "from", "the", "control", "group.", "Patients", "diagnosed", "at", "an", "age", "over", "50", "years", "and", "not", "referred", "to", "Genetic", "Counselling", "Units", "were", "considered", "as", "sporadic", "CRC.", "Samples", "from", "sporadic", "CRC", "patients", "were", "obtained", "from", "the", "Elche", "University", "Hospital", "BioBank", "and", "the", "Castellon", "Provincial", "Hospital", "BioBank.", "Written", "consent", "to", "be", "included", "in", "the", "respective", "biobanks", "was", "obtained", "from", "each", "patient.", "CRC", "patients,", "as", "index", "subjects", "from", "families", "with", "suspicion", "of", "LS", "that", "attended", "Genetic", "Counselling", "at", "the", "Cancer", "Units", "of", "the", "Elche", "and", "La", "Fe", "Hospitals,", "were", "recruited.", "The", "study", "was", "approved", "by", "the", "Ethics", "Committee", "of", "the", "Elche", "University", "Hospital." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
No familial history of cancer was available from the control group. Patients diagnosed at an age over 50 years and not referred to Genetic Counselling Units were considered as sporadic CRC. Samples from sporadic CRC patients were obtained from the Elche University Hospital BioBank and the Castellon Provincial Hospital BioBank. Written consent to be included in the respective biobanks was obtained from each patient. CRC patients, as index subjects from families with suspicion of LS that attended Genetic Counselling at the Cancer Units of the Elche and La Fe Hospitals, were recruited. The study was approved by the Ethics Committee of the Elche University Hospital.
1334229-05-Discussion-p01
[ "Mutations", "in", "exon", "3", "of", "the", "CTNNB1", "gene", "leading", "to", "loss", "of", "one", "of", "the", "phosphorylation", "sites", "were", "rare.", "Strikingly,", "all", "five", "of", "these", "mutations", "occurred", "in", "the", "proximal", "colon", "and", "three", "of", "these", "also", "had", "absent", "hMLH1", "expression.", "This", "may", "indicate", "that", "these", "proximal", "colon", "tumours,", "which", "often", "also", "show", "mismatch", "repair", "deficiency,", "are", "more", "likely", "to", "harbour", "CTNNB1", "mutations.", "This", "was", "also", "found", "in", "a", "study", "of", "microsatellite", "instable", "colorectal", "tumours", "[26].", "The", "WAVE", "screening", "technique", "has", "not", "been", "used", "previously", "for", "formalin-fixed,", "paraffin-embedded", "tissue,", "and", "therefore", "it", "seems", "plausible", "that", "samples", "harbouring", "a", "CTNNB1", "mutation", "have", "escaped", "detection.", "However,", "all", "58", "hMLH1", "deficient", "samples", "were", "analysed", "by", "direct", "sequencing", "without", "a", "prior", "screening", "step,", "and", "only", "three", "of", "these", "samples", "harboured", "a", "CTNNB1", "mutation", "patients", "cases", " ", "were", "investigated.", "The", "occurrence", "of", "mutations", "in", "the", "CTNNB1", "gene,", "which", "codes", "for", "β-catenin,", "was", "rare:", "only", "five", "of", "464", "tumours", "analysed", "were", "found", "to", "have", "a", "mutation", "at", "one", "of", "the", "phosphorylation", "sites", "in", "exon", "3.", "Truncating", "mutations", "in", "APC", "and", "activating", "mutations", "in", "K-ras", "appeared", "to", "occur", "at", "similar", "frequencies.", "Although", "tumours", "harbouring", "both", "mutations", "were", "relatively", "rare,", "mutations", "in", "APC", "and", "K-ras", "seemed", "to", "occur", "co-dependently.", "Nine", "percent", "of", "all", "tumours", "(58/656)", "lacked", "hMLH1", "expression,", "and", "in", "these", "tumours", "almost", "no", "APC", "or", "K-ras", "mutations", "was", "detected.", "Patients", "harbouring", "a", "tumour", "with", "absent", "hMLH1", "expression", "were", "older,", "more", "often", "women,", "more", "often", "had", "proximal", "colon", "tumours", "that", "showed", "poorer", "differentiation", "when", "compared", "to", "patients", "who", "harboured", "a", "tumour", "with", "an", "APC", "and/or", "K-ras", "mutation." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 9, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutations in exon 3 of the CTNNB1 gene leading to loss of one of the phosphorylation sites were rare. Strikingly, all five of these mutations occurred in the proximal colon and three of these also had absent hMLH1 expression. This may indicate that these proximal colon tumours, which often also show mismatch repair deficiency, are more likely to harbour CTNNB1 mutations. This was also found in a study of microsatellite instable colorectal tumours [26]. The WAVE screening technique has not been used previously for formalin-fixed, paraffin-embedded tissue, and therefore it seems plausible that samples harbouring a CTNNB1 mutation have escaped detection. However, all 58 hMLH1 deficient samples were analysed by direct sequencing without a prior screening step, and only three of these samples harboured a CTNNB1 mutation patients cases were investigated. The occurrence of mutations in the CTNNB1 gene, which codes for β-catenin, was rare: only five of 464 tumours analysed were found to have a mutation at one of the phosphorylation sites in exon 3. Truncating mutations in APC and activating mutations in K-ras appeared to occur at similar frequencies. Although tumours harbouring both mutations were relatively rare, mutations in APC and K-ras seemed to occur co-dependently. Nine percent of all tumours (58/656) lacked hMLH1 expression, and in these tumours almost no APC or K-ras mutations was detected. Patients harbouring a tumour with absent hMLH1 expression were older, more often women, more often had proximal colon tumours that showed poorer differentiation when compared to patients who harboured a tumour with an APC and/or K-ras mutation.
1334229-03-Methods-p01
[ "DNA", "isolation", "was", "described", "in", "detail", "elsewhere", "[27].", "Briefly,", "a", "4", "μm", "section,", "cut", "from", "each", "paraffin-embedded", "tumour", "tissue", "block,", "was", "stained", "with", "haematoxylin", "and", "eosin", "(HE)", "for", "histopathological", "examination", "by", "a", "pathologist.", "Five", "20", "μm", "sections", "of", "tumour", "tissue", "were", "cut", "from", "each", "sample", "for", "DNA", "isolation.", "Tumour", "tissue", "was", "separated", "from", "normal", "colon", "epithelium", "using", "the", "HE", "section", "as", "a", "reference.", "Genomic", "DNA", "was", "extracted", "from", "macrodissected", "tumour", "colorectal", "cancer", "between", "the", "ages", "of", "55", "and", "69", "years", "Netherlands", ",", "and", "included", "a", "total", "of", "58,279", "men", "and", "62,573", "women", "between", "the", "ages", "of", "55", "and", "69", "years", "at", "baseline." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 2, 15, 16, 16, 16, 16, 16, 16, 16, 25, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
DNA isolation was described in detail elsewhere [27]. Briefly, a 4 μm section, cut from each paraffin-embedded tumour tissue block, was stained with haematoxylin and eosin (HE) for histopathological examination by a pathologist. Five 20 μm sections of tumour tissue were cut from each sample for DNA isolation. Tumour tissue was separated from normal colon epithelium using the HE section as a reference. Genomic DNA was extracted from macrodissected tumour colorectal cancer between the ages of 55 and 69 years Netherlands , and included a total of 58,279 men and 62,573 women between the ages of 55 and 69 years at baseline.
1557864-05-Discussion-p02
[]
[]
1557864-01-Abstract-p01
[ "MSI", "was", "detected", "in", "three", "of", "the", "eight", "cell", "lines", "i.e.", "A2780", "(no", "MLH1", "mRNA", "expression", "due", "to", "promoter", "methylation),", "SKOV3", "(no", "MLH1", "mRNA", "expression)", "and", "2774", "(no", "altered", "expression", "of", "MMR", "genes).", "Overall,", "there", "was", "no", "association", "between", "cisplatin", "response", "and", "MMR", "status", "in", "these", "eight", "cell", "lines." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
MSI was detected in three of the eight cell lines i.e. A2780 (no MLH1 mRNA expression due to promoter methylation), SKOV3 (no MLH1 mRNA expression) and 2774 (no altered expression of MMR genes). Overall, there was no association between cisplatin response and MMR status in these eight cell lines.
1360090-03-Results-p01
[ "Associations", "between", "BRAF", "mutation", "and", "molecular", "features", "of", "colorectal", "cancer." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Associations between BRAF mutation and molecular features of colorectal cancer.
3034663-03-Methods-p01
[ "Concomitant", "deleterious", "variants", "were", "detected", "in", "two", "of", "the", "families:", "one", "in", "the", "MLH1", "gene", "(c.676C>T;", "p.Arg226X)", "and", "the", "other", "in", "the", "MSH6", "gene", "(c.3013C>T;", "p.Arg1005X).", "Seventeen", "affected", "and", "unaffected", "family", "members", "from", "these", "two", "families", "were", "tested", "for", "the", "pathogenic", "and", "p.Lys618Ala", "variants." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Concomitant deleterious variants were detected in two of the families: one in the MLH1 gene (c.676C>T; p.Arg226X) and the other in the MSH6 gene (c.3013C>T; p.Arg1005X). Seventeen affected and unaffected family members from these two families were tested for the pathogenic and p.Lys618Ala variants.
1334229-02-Background-p01
[ "Genetic", "instability", "is", "seen", "in", "most", "types", "of", "cancer", "[10].", "Two", "distinct", "types", "of", "genetic", "instability", "appear", "to", "occur", "in", "colorectal", "cancer", "[11]:", "chromosomal", "and", "microsatellite", "instability.", "Chromosomal", "instability", "results", "in", "gains", "or", "losses", "of", "entire", "chromosomes", "or", "parts", "of", "them,", "and", "gives", "rise", "to", "aneuploid", "tumours", "and", "occurs", "in", "the", "majority", "of", "cancers.", "A", "smaller", "proportion", "of", "colorectal", "cancers", "colorectal", "cancers", " ", "and", "is", "often", "the", "result", "of", "mutations", "in", "the", "N-terminal", "domain", "of", "the", "APC", "gene,", "that", "lead", "to", "partial", "or", "complete", "loss", "of", "this", "region", "and", "thereby", "to", "loss", "of", "the", "β-catenin", "regulating", "function", "[5,6].", "Conversely,", "in", "tumours", "lacking", "these", "APC", "mutations", "[7],", "activating", "missense", "mutations", "at", "one", "of", "the", "phosphorylation", "sites", "at", "codons", "31,", "33,", "37", "and", "45", "of", "exon", "3", "of", "the", "CTNNB1", "gene", "(encoding", "the", "β-catenin", "protein)", "can", "render", "it", "stable", "as", "it", "can", "no", "longer", "be", "tagged", "for", "cellular", "degradation.", "Activation", "of", "the", "Ras", "pathway", "in", "cancer", "is", "marked", "by", "the", "loss", "of", "the", "intrinsic", "GTPase", "activity", "of", "the", "Ras", "protein,", "which", "can", "be", "ascribed", "to", "missense", "mutations", "in", "codons", "12", "and", "13", "of", "exon", "1,", "which", "are", "responsible", "for", "90%", "activating", "mutations", "in", "the", "of", "the", "K-ras", "gene", "[8]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 1, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Genetic instability is seen in most types of cancer [10]. Two distinct types of genetic instability appear to occur in colorectal cancer [11]: chromosomal and microsatellite instability. Chromosomal instability results in gains or losses of entire chromosomes or parts of them, and gives rise to aneuploid tumours and occurs in the majority of cancers. A smaller proportion of colorectal cancers colorectal cancers and is often the result of mutations in the N-terminal domain of the APC gene, that lead to partial or complete loss of this region and thereby to loss of the β-catenin regulating function [5,6]. Conversely, in tumours lacking these APC mutations [7], activating missense mutations at one of the phosphorylation sites at codons 31, 33, 37 and 45 of exon 3 of the CTNNB1 gene (encoding the β-catenin protein) can render it stable as it can no longer be tagged for cellular degradation. Activation of the Ras pathway in cancer is marked by the loss of the intrinsic GTPase activity of the Ras protein, which can be ascribed to missense mutations in codons 12 and 13 of exon 1, which are responsible for 90% activating mutations in the of the K-ras gene [8].
1334229-03-Methods-p03
[ "Analysis", "of", "the", "BAT-26", "mononucleotide", "repeat", "was", "performed", "in", "a", "random", "sample", "of", "tumour", "specimens", "from", "114", "patients,", "and", "a", "series", "of", "48", "of", "58", "tumours", "that", "lacked", "hMLH1", "expression,", "to", "assess", "the", "concordance", "between", "the", "microsatellite", "instability", "marker", "BAT-26", "and", "hMLH1", "expression.", "The", "primer", "sequences", "and", "PCR", "conditions", "for", "the", "BAT-26", "mononucleotide", "repeat", "were", "used", "as", "described", "previously", "[31]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Analysis of the BAT-26 mononucleotide repeat was performed in a random sample of tumour specimens from 114 patients, and a series of 48 of 58 tumours that lacked hMLH1 expression, to assess the concordance between the microsatellite instability marker BAT-26 and hMLH1 expression. The primer sequences and PCR conditions for the BAT-26 mononucleotide repeat were used as described previously [31].
1373649-03-Methods-p01
[ "As", "screening", "method", "for", "HNPCC", "III:3", "colon", "cancer", " ", "in", "the", "proband", "and", "the", "study", "of", "the", "family's", "pedigree", "(fig.", "1),", "that", "fulfill", "the", "strict", "Amsterdam-1", "criteria,", "prompted", "genetic", "analysis", "with", "suspicion", "of", "HNPCC.", "They", "were", "informed", "about", "the", "risks,", "benefits", "and", "limitations", "of", "the", "study", "protocol." ]
[ 0, 0, 0, 0, 1, 9, 1, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
As screening method for HNPCC III:3 colon cancer in the proband and the study of the family's pedigree (fig. 1), that fulfill the strict Amsterdam-1 criteria, prompted genetic analysis with suspicion of HNPCC. They were informed about the risks, benefits and limitations of the study protocol.
2275286-01-Abstract-p01
[ "Thirty-four", "out", "of", "the", "146", "colorectal", "cancers", "(CRCs,", "23.2%)", "were", "MSI,", "including", "19", "MSI-H", "CRCs", "and", "15", "MSI-L", "CRCS.", "Negative", "staining", "for", "MSH2", "was", "found", "in", "8", "CRCs,", "negative", "staining", "for", "MSH6", "was", "found", "in", "6", "CRCs.", "One", "MSI-H", "CRC", "was", "negative", "for", "both", "MSH6", "and", "MSH2.", "Seventeen", "CRCs", "stained", "negatively", "for", "MLH1.", "MLH1", "promoter", "methylation", "was", "determined", "in", "34", "MSI", "CRCs.", "Hypermethylation", "of", "the", "MLH1", "promoter", "occurred", "in", "14", "(73.7%)", "out", "of", "19", "MSI-H", "CRCs", "and", "5", "(33.3%)", "out", "of", "15", "MSI-L", "CRCs.", "Among", "the", "34", "MSI", "carriers", "and", "one", "MSS", "CRC", "with", "MLH1", "negative", "staining", ",", "8", "had", "a", "MMR", "gene", "germline", "mutation,", "which", "accounted", "for", "23.5%", "of", "all", "MSI", "colorectal", "cancers", "MMR", " ", "gene", "germline", "mutation", ",", "which", "accounted", "for", "23.5%", "of", "all", "MSI", "15", "Hereditary", "nonpolyposis", "colorectal", "cancer", "colorectal", "cancer" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 23, 24, 24, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 21, 0, 0, 5, 6, 0, 0, 0, 0, 0, 0, 0, 19, 11, 1, 2, 2, 2, 1, 2 ]
Thirty-four out of the 146 colorectal cancers (CRCs, 23.2%) were MSI, including 19 MSI-H CRCs and 15 MSI-L CRCS. Negative staining for MSH2 was found in 8 CRCs, negative staining for MSH6 was found in 6 CRCs. One MSI-H CRC was negative for both MSH6 and MSH2. Seventeen CRCs stained negatively for MLH1. MLH1 promoter methylation was determined in 34 MSI CRCs. Hypermethylation of the MLH1 promoter occurred in 14 (73.7%) out of 19 MSI-H CRCs and 5 (33.3%) out of 15 MSI-L CRCs. Among the 34 MSI carriers and one MSS CRC with MLH1 negative staining , 8 had a MMR gene germline mutation, which accounted for 23.5% of all MSI colorectal cancers MMR gene germline mutation , which accounted for 23.5% of all MSI 15 Hereditary nonpolyposis colorectal cancer colorectal cancer
1373649-02-Background-p01
[ "A", "much", "less", "labor-intensive", "alternative", "method", "used", "to", "prescreen", "high-risk", "individuals", "for", "further", "germline", "mutation", "analysis", "is", "immunohistochemistry", "(IHC)", "testing", "for", "MLH1", "and", "MSH2", "expression.", "IHC", "testing", "may", "identify", "which", "gene", "to", "target", "for", "analysis." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
A much less labor-intensive alternative method used to prescreen high-risk individuals for further germline mutation analysis is immunohistochemistry (IHC) testing for MLH1 and MSH2 expression. IHC testing may identify which gene to target for analysis.
3034663-04-Results-p01
[ "*Individuals", "from", "apparently", "unrelated", "families" ]
[ 0, 0, 0, 0, 0 ]
*Individuals from apparently unrelated families
1334229-05-Discussion-p01
[ "Mutations", "in", "exon", "3", "of", "the", "CTNNB1", "gene", "leading", "to", "loss", "of", "one", "of", "the", "phosphorylation", "sites", "were", "rare.", "Strikingly,", "all", "five", "of", "these", "mutations", "occurred", "in", "the", "proximal", "colon", "and", "three", "of", "these", "also", "had", "absent", "hMLH1", "expression.", "This", "may", "indicate", "that", "these", "proximal", "colon", "tumours,", "which", "often", "also", "show", "mismatch", "repair", "deficiency,", "are", "more", "likely", "to", "harbour", "CTNNB1", "CTNNB1", "CTNNB1", "CTNNB1", " ", "and", "K-ras", "genes", "as", "well", "as", "expression", "of", "the", "hMLH1", "protein", "in", "tumour", "tissue", "of", "656", "sporadic", "colorectal", "cancer", "cases", "were", "investigated.", "The", "occurrence", "of", "mutations", "in", "the", "CTNNB1", "gene,", "which", "codes", "for", "β-catenin,", "was", "rare:", "only", "five", "of", "464", "tumours", "analysed", "were", "found", "to", "have", "a", "mutation", "at", "one", "of", "the", "phosphorylation", "sites", "in", "exon", "3.", "Truncating", "mutations", "in", "APC", "and", "activating", "mutations", "in", "K-ras", "appeared", "to", "occur", "at", "similar", "frequencies.", "Although", "tumours", "harbouring", "both", "mutations", "were", "relatively", "rare,", "mutations", "in", "APC", "and", "K-ras", "seemed", "to", "occur", "co-dependently.", "Nine", "percent", "of", "all", "tumours", "(58/656)", "lacked", "hMLH1", "expression,", "and", "in", "these", "tumours", "almost", "no", "APC", "or", "K-ras", "mutations", "was", "detected.", "Patients", "harbouring", "a", "tumour", "with", "absent", "hMLH1", "expression", "were", "older,", "more", "often", "women,", "more", "often", "had", "proximal", "colon", "tumours", "that", "showed", "poorer", "differentiation", "when", "compared", "to", "patients", "who", "harboured", "a", "tumour", "with", "an", "APC", "and/or", "K-ras", "mutation." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 21, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutations in exon 3 of the CTNNB1 gene leading to loss of one of the phosphorylation sites were rare. Strikingly, all five of these mutations occurred in the proximal colon and three of these also had absent hMLH1 expression. This may indicate that these proximal colon tumours, which often also show mismatch repair deficiency, are more likely to harbour CTNNB1 CTNNB1 CTNNB1 CTNNB1 and K-ras genes as well as expression of the hMLH1 protein in tumour tissue of 656 sporadic colorectal cancer cases were investigated. The occurrence of mutations in the CTNNB1 gene, which codes for β-catenin, was rare: only five of 464 tumours analysed were found to have a mutation at one of the phosphorylation sites in exon 3. Truncating mutations in APC and activating mutations in K-ras appeared to occur at similar frequencies. Although tumours harbouring both mutations were relatively rare, mutations in APC and K-ras seemed to occur co-dependently. Nine percent of all tumours (58/656) lacked hMLH1 expression, and in these tumours almost no APC or K-ras mutations was detected. Patients harbouring a tumour with absent hMLH1 expression were older, more often women, more often had proximal colon tumours that showed poorer differentiation when compared to patients who harboured a tumour with an APC and/or K-ras mutation.
1266026-05-Discussion-p03
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1619718-02-Introduction-p01
[ "In", "recent", "years,", "the", "fundamental", "division", "of", "colorectal", "polyps", "into", "precancerous", "adenomas", "and", "innocent", "HPs", "has", "begun", "to", "erode", "and", "the", "concept", "of", "an", "alternative", "serrated", "pathway", "has", "gained", "support.", "This", "revision", "began", "with", "the", "description", "of", "an", "intermediate", "lesion", "described", "as", "serrated", "adenoma", "(SA).10", "Initially,", "however,", "SA", "was", "not", "conceived", "as", "an", "intermediate", "category", "of", "polyp", "but", "essentially", "as", "an", "adenoma", "with", "a", "superimposed", "serrated", "architecture", "that", "conferred", "only", "a", "superficial", "likeness", "to", "a", "HP.10", "Additionally,", "the", "mixed", "polyp", "(MP)", "was", "perceived", "as", "a", "chance", "collision", "between", "a", "HP", "and", "an", "adenoma,", "giving", "a", "combined", "polyp.", "These", "preliminary", "interpretations", "did", "not", "represent", "a", "major", "departure", "from", "the", "traditional", "classification", "of", "colorectal", "polyps", "but", "preserved", "the", "fundamental", "distinction", "of", "neoplastic", "adenomas", "adenoma", "bi-allelic", "inactivation", " ", "of", "APC,", "followed", "by", "oncogenic", "KRAS", "mutation", "and", "culminating", "in", "inactivation", "of", "TP53", "at", "the", "transition", "from", "adenoma", "to", "carcinoma.5", "While", "there", "is", "good", "evidence", "that", "KRAS", "mutation", "is", "associated", "with", "advanced", "adenoma", "features6", "and", "could", "therefore", "be", "used", "as", "objective", "evidence", "of", "aggression,", "this", "approach", "has", "a", "number", "of", "limitations.", "First,", "KRAS", "mutation", "also", "occurs", "frequently", "in", "dysplastic", "aberrant", "crypt", "foci", "(microadenomas)", "and", "in", "some", "small", "tubular", "adenomas,", "suggesting", "that", "KRAS", "mutation", "may", "initiate", "a", "subset", "of", "small", "adenomas", "with", "limited", "potential", "for", "progression.6,7", "Second,", "around", "70%", "of", "CRCs", "lack", "mutation", "of", "KRAS.8", "From", "this", "it", "follows", "that", "most", "of", "the", "precancerous", "lesions", "that", "eventually", "become", "cancers", "do", "not", "in", "fact", "have", "KRAS", "mutation.", "There", "is", "increasing", "evidence", "that", "CRC", "evolves", "through", "a", "number", "of", "pathways", "and", "the", "traditional", "adenoma–carcinoma", "sequence,", "with", "its", "accompanying", "genetic", "steps,", "provides", "a", "surprisingly", "narrow", "window", "of", "understanding", "of", "this", "multipathway", "reality.9" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 5, 6, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In recent years, the fundamental division of colorectal polyps into precancerous adenomas and innocent HPs has begun to erode and the concept of an alternative serrated pathway has gained support. This revision began with the description of an intermediate lesion described as serrated adenoma (SA).10 Initially, however, SA was not conceived as an intermediate category of polyp but essentially as an adenoma with a superimposed serrated architecture that conferred only a superficial likeness to a HP.10 Additionally, the mixed polyp (MP) was perceived as a chance collision between a HP and an adenoma, giving a combined polyp. These preliminary interpretations did not represent a major departure from the traditional classification of colorectal polyps but preserved the fundamental distinction of neoplastic adenomas adenoma bi-allelic inactivation of APC, followed by oncogenic KRAS mutation and culminating in inactivation of TP53 at the transition from adenoma to carcinoma.5 While there is good evidence that KRAS mutation is associated with advanced adenoma features6 and could therefore be used as objective evidence of aggression, this approach has a number of limitations. First, KRAS mutation also occurs frequently in dysplastic aberrant crypt foci (microadenomas) and in some small tubular adenomas, suggesting that KRAS mutation may initiate a subset of small adenomas with limited potential for progression.6,7 Second, around 70% of CRCs lack mutation of KRAS.8 From this it follows that most of the precancerous lesions that eventually become cancers do not in fact have KRAS mutation. There is increasing evidence that CRC evolves through a number of pathways and the traditional adenoma–carcinoma sequence, with its accompanying genetic steps, provides a surprisingly narrow window of understanding of this multipathway reality.9
1557864-05-Discussion-p03
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
3034663-04-Results-p01
[ "Results", "of", "case-control", "and", "case-case", "analyses.", "Odds", "ratios", "(ORs)", "and", "95%", "confidence", "intervals", "(95%", "CIs)", "for", "the", "p.Lys618Ala", "variant" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Results of case-control and case-case analyses. Odds ratios (ORs) and 95% confidence intervals (95% CIs) for the p.Lys618Ala variant
1601966-03-Results-p01
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1360090-03-Results-p01
[ "a", "Data", "was", "unavailable", "for", "gender", "in", "43", "cases,", "infiltrating", "lymphocytes", "in", "55", "cases,", "nodal", "involvement", "in", "77", "cases,", "tumor", "site", "in", "56", "cases,", "grade", "in", "106", "cases", "and", "mucinous", "appearance", "in", "89", "cases." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
a Data was unavailable for gender in 43 cases, infiltrating lymphocytes in 55 cases, nodal involvement in 77 cases, tumor site in 56 cases, grade in 106 cases and mucinous appearance in 89 cases.
1619718-05-Discussion-p01
[ "The", "adenomas", "in", "this", "study", "were", "grouped", "as", "TAs", "<", " ", "10", "mm,", "TAs", ">", " ", "10", "mm", "and", "TVAs", ">", " ", "10", "mm", "TAs", "<", " ", "10", "mm", ",", "TAs", ">", " ", "10", "mm", "and", "TVAs/VAs.", "Overall,", "KRAS", "mutation", "occurred", "in", "26.5%", "of", "adenomas", "while", "BRAF", "mutation", "was", "detected", "in", "only", "4.8%.", "Three", "of", "the", "four", "BRAF", "mutations", "occurred", "in", "adenomas", "that", "also", "had", "KRAS", "mutation.", "It", "is", "well", "established", "that", "BRAF", "and", "KRAS", "mutation", "rarely", "occur", "in", "the", "same", "colorectal", "neoplasm.12,16,30", "Furthermore,", "BRAF", "mutations", "are", "much", "more", "typical", "of", "serrated", "polyps", "than", "adenomas.14,31", "The", "assay", "for", "BRAF", "mutation", "used", "in", "this", "study", "was", "highly", "sensitive", "and", "it", "is", "possible", "that", "the", "mutation", "was", "being", "identified", "in", "normal", "mucosa", "included", "with", "the", "polyp.", "KRAS", "mutation", "may", "occur", "within", "apparently", "normal", "colorectal", "mucosa", "and", "the", "same", "could", "apply", "to", "BRAF.32", "Therefore,", "the", "finding", "of", "BRAF", "mutation", "in", "a", "small", "subset", "of", "adenomas", "could", "be", "spurious", "and", "the", "true", "incidence", "of", "BRAF", "mutation", "in", "colorectal", "adenomas", "could", "be", "lower", "than", "4.8%.", "BRAF", "mutation", "frequencies", "of", "0%14", "and", "3%31", "have", "been", "reported", "in", "other", "series", "of", "colorectal", "adenomas." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The adenomas in this study were grouped as TAs <   10 mm, TAs >   10 mm and TVAs >   10 mm TAs <   10 mm , TAs >   10 mm and TVAs/VAs. Overall, KRAS mutation occurred in 26.5% of adenomas while BRAF mutation was detected in only 4.8%. Three of the four BRAF mutations occurred in adenomas that also had KRAS mutation. It is well established that BRAF and KRAS mutation rarely occur in the same colorectal neoplasm.12,16,30 Furthermore, BRAF mutations are much more typical of serrated polyps than adenomas.14,31 The assay for BRAF mutation used in this study was highly sensitive and it is possible that the mutation was being identified in normal mucosa included with the polyp. KRAS mutation may occur within apparently normal colorectal mucosa and the same could apply to BRAF.32 Therefore, the finding of BRAF mutation in a small subset of adenomas could be spurious and the true incidence of BRAF mutation in colorectal adenomas could be lower than 4.8%. BRAF mutation frequencies of 0%14 and 3%31 have been reported in other series of colorectal adenomas.
1334229-03-Methods-p01
[ "DNA", "isolation" ]
[ 0, 0 ]
DNA isolation
3034663-03-Methods-p01
[ "Concomitant", "deleterious", "variants", "were", "detected", "in", "two", "of", "the", "families:", "one", "in", "the", "MLH1", "gene", "(c.676C>T;", "p.Arg226X)", "and", "the", "other", "in", "the", "MSH6", "gene", "(c.3013C>T;", "p.Arg1005X).", "Seventeen", "affected", "and", "unaffected", "family", "members", "from", "these", "two", "families", "were", "tested", "for", "the", "pathogenic", "and", "p.Lys618Ala", "variants." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Concomitant deleterious variants were detected in two of the families: one in the MLH1 gene (c.676C>T; p.Arg226X) and the other in the MSH6 gene (c.3013C>T; p.Arg1005X). Seventeen affected and unaffected family members from these two families were tested for the pathogenic and p.Lys618Ala variants.
1619718-05-Discussion-p01
[ "In", "previous", "studies", "of", "KRAS", "in", "colorectal", "adenomas,", "mutation", "has", "been", "associated", "negatively", "with", "flat", "and", "depressed", "TAs", "and", "positively", "with", "polypoid", "appearance,", "increasing", "size,", "dysplasia,", "villous", "change", "and", "synchronous", "colorectal", "cancer.6,33–35", "In", "by", "far", "the", "largest", "study,", "which", "included", "738", "adenomas", "obtained", "from", "639", "participants", "in", "a", "dietary", "intervention", "trial,", "multivariate", "analysis", "showed", "that", "the", "independent", "predictors", "of", "KRAS", "mutation", "were", "age", "of", "subject,", "presence", "of", "villous", "architecture", "and", "high-grade", "dysplasia,", "but", "not", "size", "of", "adenoma.6", "It", "is", "well", "known", "that", "adenoma", "size,", "dysplasia", "and", "villous", "architecture", "are", "interrelated", "and", "account", "has", "to", "be", "taken", "of", "this", "in", "assessing", "results.", "In", "this", "study", "KRAS", "mutation", "occurred", "with", "the", "same", "frequency", "in", "small", "(18%)", "and", "large", "(17%)", "adenomas", "but", "was", "significantly", "more", "frequent", "in", "adenomas", "that", "included", "a", "villous", "architecture", "(50%).", "A", "previous", "study", "showed", "a", "very", "high", "frequency", "of", "KRAS", "mutation", "(93%)", "in", "flat", "adenomas", "with", "a", "tubulovillous", "architecture.34", "We", "would", "agree", "with", "the", "suggestion", "that", "KRAS", "mutation", "is", "linked", "with", "the", "development", "of", "villous", "change", "and", "does", "not", "influence", "adenoma", "growth", "in", "an", "independent", "manner.6", "In", "this", "study,", "high-grade", "dysplasia", "was", "diagnosed", "only", "when", "it", "amounted", "to", "carcinoma", "in", "situ.", "This", "was", "observed", "in", "none", "of", "the", "84", "adenomas", "but", "in", "four", "serrated", " ", "polyps", "adenomas", " ", "but", "in", "four", "serrated", "polyps", "738", "mucosa", "polyps", "serrated", " ", "polyps", "and", "will", "then", "conclude", "with", "the", "concept", "that", "features", "of", "these", "two", "types", "of", "polyp", " ", "can", "co-occur", "or", "become", "‘fused’", "in", "subtypes", "of", "advanced", "polyps", "with", "mixed", "cytomorphology", "(hyperplastic", "and", "dysplastic)", "and", "a", "serrated", "and/or", "villous", "architecture." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 17, 0, 1, 9, 0, 0, 0, 0, 0, 9, 11, 3, 1, 17, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In previous studies of KRAS in colorectal adenomas, mutation has been associated negatively with flat and depressed TAs and positively with polypoid appearance, increasing size, dysplasia, villous change and synchronous colorectal cancer.6,33–35 In by far the largest study, which included 738 adenomas obtained from 639 participants in a dietary intervention trial, multivariate analysis showed that the independent predictors of KRAS mutation were age of subject, presence of villous architecture and high-grade dysplasia, but not size of adenoma.6 It is well known that adenoma size, dysplasia and villous architecture are interrelated and account has to be taken of this in assessing results. In this study KRAS mutation occurred with the same frequency in small (18%) and large (17%) adenomas but was significantly more frequent in adenomas that included a villous architecture (50%). A previous study showed a very high frequency of KRAS mutation (93%) in flat adenomas with a tubulovillous architecture.34 We would agree with the suggestion that KRAS mutation is linked with the development of villous change and does not influence adenoma growth in an independent manner.6 In this study, high-grade dysplasia was diagnosed only when it amounted to carcinoma in situ. This was observed in none of the 84 adenomas but in four serrated polyps adenomas but in four serrated polyps 738 mucosa polyps serrated polyps and will then conclude with the concept that features of these two types of polyp can co-occur or become ‘fused’ in subtypes of advanced polyps with mixed cytomorphology (hyperplastic and dysplastic) and a serrated and/or villous architecture.
1334229-03-Methods-p03
[ "In", "the", "statistical", "analysis,", "data", "from", "656", "patients", "for", "whom", "information", "on", "APC", "and", "K-ras", "mutation", "status", "as", "well", "as", "hMLH1", "expression", "was", "complete", "were", "included." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In the statistical analysis, data from 656 patients for whom information on APC and K-ras mutation status as well as hMLH1 expression was complete were included.
1360090-04-Discussion-p01
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1360090-03-Results-p01
[ "Associations", "between", "BRAF", "mutation", "and", "molecular", "features", "of", "colorectal", "cancer." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Associations between BRAF mutation and molecular features of colorectal cancer.
1619718-02-Introduction-p02
[ "This", "paper", "explores", "the", "possibility", "that", "the", "early", "evolution", "of", "colorectal", "cancer", "is", "not", "limited", "to", "two", "essentially", "independent", "pathways,", "but", "often", "combines", "components", "of", "these", "pathways.", "Indeed,", "the", "successful", "‘fusion’", "of", "the", "hyperproliferation", "and", "crypt", "fission", "that", "characterize", "adenomas21", "with", "the", "inhibition", "of", "apoptosis", "that", "has", "been", "linked", "with", "serrated", "polyps22,23", "may", "generate", "lesions", "with", "enhanced", "aggressiveness.", "Specifically,", "it", "is", "suggested", "that", "methylation", "of", "the", "DNA", "repair", "gene", "O-6-methylguanine", "DNA", "methyltransferase", "mutation", " ", "of", "BRAF", "and", "extensive", "DNA", "methylation.12", "This", "viewpoint", "was", "consolidated", "through", "the", "formal", "recognition", "of", "two", "largely", "independent", "pathways", "of", "colorectal", "tumorigenesis:", "(i)", "the", "traditional", "adenoma–carcinoma", "sequence", "associated", "with", "chomosomally", "unstable", "CRCs,13", "and", "(ii)", "the", "‘serrated", "pathway’", "culminating", "in", "CRCs", "with", "DNA", "microsatellite", "instability", "(MSI),", "mutation", "of", "BRAF", "and", "extensive", "DNA", "methylation.12,14–20" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 7, 8, 8, 8, 8, 8, 8, 8, 8, 5, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
This paper explores the possibility that the early evolution of colorectal cancer is not limited to two essentially independent pathways, but often combines components of these pathways. Indeed, the successful ‘fusion’ of the hyperproliferation and crypt fission that characterize adenomas21 with the inhibition of apoptosis that has been linked with serrated polyps22,23 may generate lesions with enhanced aggressiveness. Specifically, it is suggested that methylation of the DNA repair gene O-6-methylguanine DNA methyltransferase mutation of BRAF and extensive DNA methylation.12 This viewpoint was consolidated through the formal recognition of two largely independent pathways of colorectal tumorigenesis: (i) the traditional adenoma–carcinoma sequence associated with chomosomally unstable CRCs,13 and (ii) the ‘serrated pathway’ culminating in CRCs with DNA microsatellite instability (MSI), mutation of BRAF and extensive DNA methylation.12,14–20
3034663-04-Results-p01
[ "Results", "of", "case-control", "and", "case-case", "analyses.", "Odds", "ratios", "(ORs)", "and", "95%", "confidence", "intervals", "(95%", "CIs)", "for", "the", "p.Lys618Ala", "variant" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Results of case-control and case-case analyses. Odds ratios (ORs) and 95% confidence intervals (95% CIs) for the p.Lys618Ala variant
2386495-03-Methods-p01
[ "Patients", "without", "any", "detected", "mutation", "in", "APC", "or", "MUTYH", "FAP", "Probands", "196", " ", "families", "with", "verified", "FAP", "(defined", "as", "more", "than", "100", "colorectal", "adenomas", "or", "if", "less", "with", "a", "family", "history", "of", "FAP).", "Sixty-one", "of", "these", "families", "are", "now", "extinct", "but", "135", "families", "with", "at", "least", "one", "living", "disease-affected", "member", "remain.", "Presently,", "315", "disease-affected", "living", "patients", "are", "included", "in", "the", "registry.", "The", "geographical", "catchment", "area", "comprises", "the", "whole", "of", "Sweden.", "Details", "of", "how", "patients", "have", "been", "eligible", "for", "accession", "into", "the", "registry", "are", "given", "in", "[30].", "In", "this", "study", "we", "have", "analyzed", "96", "families", "included", "in", "the", "registry", "for", "mutations", "in", "the", "APC", "gene.", "Twenty-four", "of", "the", "remaining", "39", "families", "have", "been", "analyzed", "for", "APC", "gene", "mutations", "at", "other", "genetic", "laboratories", "and", "15", "families", "remain", "to", "be", "tested.", "We", "have", "previously", "reported", "six", "of", "these", "patients", "who", "carried", "bi-allelic", "MUTYH", "mutations", "[31].", "Probands", "were", "defined", "as", "those", "diagnosed", "on", "the", "basis", "of", "the", "occurrence", "of", "symptoms", "and", "irrespective", "of", "other", "cases", "in", "the", "family", "and", "call-up", "patients,", "as", "those", "identified", "as", "subjects", "at", "risk", "on", "the", "basis", "of", "studies", "of", "pedigrees", "and", "found", "to", "have", "FAP.", "De", "novo", "mutations", "were", "defined", "in", "those", "individuals", "where", "none", "of", "the", "parents", "carried", "the", "mutation", "or", "where", "the", "parents", "had", "a", "negative", "colonoscopy", "after", "the", "age", "of", "50", "or", "died", "of", "a", "non-FAP", "related", "cause", "after", "the", "age", "of", "75.", "All", "patients", "have", "given", "their", "consent", "and", "the", "local", "ethics", "committees", "have", "approved", "the", "study.", "The", "clinical", "features", "of", "index", "patients", "of", "each", "of", "the", "families", "analyzed", "are", "listed", "in", "Additional", "file", "1", "and", "Table", "1." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 21, 1, 9, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Patients without any detected mutation in APC or MUTYH FAP Probands 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1.
2275286-01-Abstract-p01
[ "Thirty-four", "out", "of", "the", "146", "colorectal", "cancers", "(CRCs,", "23.2%)", "were", "MSI,", "including", "19", "MSI-H", "CRCs", "and", "15", "MSI-L", "CRCS.", "Negative", "staining", "for", "MSH2", "was", "found", "in", "8", "CRCs,", "negative", "staining", "for", "MSH6", "was", "found", "in", "6", "CRCs.", "One", "MSI-H", "CRC", "was", "negative", "for", "both", "MSH6", "and", "MSH2.", "Seventeen", "CRCs", "stained", "negatively", "for", "MLH1.", "MLH1", "promoter", "methylation", "was", "determined", "in", "34", "MSI", "CRCs.", "Hypermethylation", "of", "the", "MLH1", "promoter", "occurred", "in", "14", "(73.7%)", "out", "of", "19", "MSI-H", "CRCs", "and", "5", "(33.3%)", "out", "of", "15", "MSI-L", "CRCs.", "Among", "the", "34", "MSI", "carriers", "and", "one", "MSS", "CRC", "with", "MLH1", "negative", "staining,", "8", "had", "a", "MMR", "gene", "germline", "mutation,", "which", "accounted", "for", "23.5%", "of", "all", "MSI", "colorectal", "cancers", "and", "5.5%", "of", "all", "the", "colorectal", "cancers.", "Five", "patients", "harbored", "MSH2", "germline", "mutations,", "and", "three", "patients", "harbored", "MSH6", "germline", "mutations.", "None", "of", "the", "patients", "had", "an", "MLH1", "mutation.", "Mutations", "were", "commonly", "located", "in", "exon", "7", "and", "12", "of", "MSH2", "and", "exon", "5", "of", "MSH6.", "Right", "colonic", "lesions", "and", "mucinous", "carcinoma", "were", "not", "common", "in", "MSI", "carriers", "HNPCC", ")", "is", "an", "autosomal", "dominant", "syndrome.", "The", "National", "Cancer", "Institute", "(NCI)", "has", "recommended", "the", "Revised", "Bethesda", "guidelines", "for", "screening", "HNPCC.", "There", "has", "been", "a", "great", "deal", "of", "research", "on", "the", "value", "of", "these", "tests", "in", "other", "countries.", "However,", "literature", "about", "the", "Chinese", "population", "is", "scarce.", "Our", "objective", "is", "to", "detect", "and", "study", "microsatellite", "instability", "(MSI)", "and", "mismatch", "repair", "(MMR)", "gene", "germline", "mutation", "carriers", "among", "a", "Chinese", "population", "with", "colorectal", "cancer." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Thirty-four out of the 146 colorectal cancers (CRCs, 23.2%) were MSI, including 19 MSI-H CRCs and 15 MSI-L CRCS. Negative staining for MSH2 was found in 8 CRCs, negative staining for MSH6 was found in 6 CRCs. One MSI-H CRC was negative for both MSH6 and MSH2. Seventeen CRCs stained negatively for MLH1. MLH1 promoter methylation was determined in 34 MSI CRCs. Hypermethylation of the MLH1 promoter occurred in 14 (73.7%) out of 19 MSI-H CRCs and 5 (33.3%) out of 15 MSI-L CRCs. Among the 34 MSI carriers and one MSS CRC with MLH1 negative staining, 8 had a MMR gene germline mutation, which accounted for 23.5% of all MSI colorectal cancers and 5.5% of all the colorectal cancers. Five patients harbored MSH2 germline mutations, and three patients harbored MSH6 germline mutations. None of the patients had an MLH1 mutation. Mutations were commonly located in exon 7 and 12 of MSH2 and exon 5 of MSH6. Right colonic lesions and mucinous carcinoma were not common in MSI carriers HNPCC ) is an autosomal dominant syndrome. The National Cancer Institute (NCI) has recommended the Revised Bethesda guidelines for screening HNPCC. There has been a great deal of research on the value of these tests in other countries. However, literature about the Chinese population is scarce. Our objective is to detect and study microsatellite instability (MSI) and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
1334229-04-Results-p02
[ "Next,", "we", "compared", "the", "patient", "and", "tumour", "characteristics", "of", "tumours", "harbouring", "a", "truncating", "APC", " ", "and/or", "an", "activating", "K-ras", "mutation", "to", "those", "of", "tumours", "without", "hMLH1", "expression,", "and", "these", "results", "are", "presented", "in", "table", "4.", "Patients", "harbouring", "hMLH1", "deficient", "tumours", "were", "slightly", "older", "when", "diagnosed", "with", "colorectal", "cancer", "(69.3", "yr", "(68.0–70.5)", "versus", "67.8", "(67.4–68.3),", "P", "=", "0.03),", "were", "relatively", "less", "frequently", "men", "(40%", "versus", "58%,", "P", "=", "0.02).", "Tumours", "without", "hMLH1", "expression", "occurred", "relatively", "more", "frequently", "in", "the", "proximal", "colon", "(P", "<", "0.001)", "and", "relatively", "more", "frequently", "showed", "poor", "differentiation", "or", "are", "undifferentiated", "(P", "<", "0.001)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Next, we compared the patient and tumour characteristics of tumours harbouring a truncating APC and/or an activating K-ras mutation to those of tumours without hMLH1 expression, and these results are presented in table 4. Patients harbouring hMLH1 deficient tumours were slightly older when diagnosed with colorectal cancer (69.3 yr (68.0–70.5) versus 67.8 (67.4–68.3), P = 0.03), were relatively less frequently men (40% versus 58%, P = 0.02). Tumours without hMLH1 expression occurred relatively more frequently in the proximal colon (P < 0.001) and relatively more frequently showed poor differentiation or are undifferentiated (P < 0.001).
1557864-03-Methods-p01
[ "Microsatellite", "analysis", "and", "methylation", "specific", "PCR", "(MSP)", "were", "performed", "on", "DNA", "from", "eight", "ovarian", "cancer", "cell", "lines,", "75", "ovarian", "cancer", "specimens", "(part", "of", "a", "collection", "of", "ovarian", "tumor", "specimens", "described", "by", "us", "previously", "[39])", "and", "the", "four", "normal", "stromal", "ovarian", "ovarian", "ovarian", "ovarian", "ovarian", "cancer", " ", "cell", "lines", "SW480", "and", "SW48,", "included", "as", "controls,", "were", "cultured", "in", "RPMI", "1640", "with", "5%", "fetal", "calf", "serum", "and", "DMEM/HAMF12", "with", "10%", "fetal", "calf", "serum", "respectively.", "The", "ovarian", "cancer", "cell", "line", "A2780", "has", "been", "cultured", "separately", "in", "two", "different", "research", "laboratories", "at", "our", "department.", "The", "isolated", "DNA", "and", "RNA", "from", "each", "culture", "were", "used", "for", "further", "analysis." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 3, 3, 3, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Microsatellite analysis and methylation specific PCR (MSP) were performed on DNA from eight ovarian cancer cell lines, 75 ovarian cancer specimens (part of a collection of ovarian tumor specimens described by us previously [39]) and the four normal stromal ovarian ovarian ovarian ovarian ovarian cancer cell lines SW480 and SW48, included as controls, were cultured in RPMI 1640 with 5% fetal calf serum and DMEM/HAMF12 with 10% fetal calf serum respectively. The ovarian cancer cell line A2780 has been cultured separately in two different research laboratories at our department. The isolated DNA and RNA from each culture were used for further analysis.
1334229-03-Methods-p02
[ "All", "464", "samples", "without", "a", "truncating", "APC", "mutation", " ", "(n", "=", "411)", "and", "all", "samples", "with", "absent", "hMLH1", "expression", "(n", "=", "58)", "were", "analysed", "for", "mutations", "in", "the", "phosphorylation", "sites", "at", "codons", "33,", "37,", "41", "and", "45", "in", "exon", "3", "absent", "hMLH1", "expression", "without", "a", "truncating", "APC", "mutation", " ", "(n", "=", "411)", "and", "all", "samples", "with", "absent", "hMLH1", "expression", "(n", "=", "58)", "were", "analysed", "for", "mutations", "in", "the", "phosphorylation", "sites", "at", "codons", "33,", "37,", "41", "and", "45", "in", "exon", "3", "of", "the", "CTNNB1", "gene.", "This", "selection", "was", "made,", "since", "most", "mutations", "are", "expected", "in", "these", "samples.", "Tumours", "lacking", "truncating", "APC", " ", "mutations", "may", "harbour", "CTNNB1", "mutations", "[7],", "and", "microsatellite", "instable", "tumours", "are", "also", "expected", "to", "more", "frequently", "have", "mutations", "in", "CTNNB1", "[26]." ]
[ 0, 0, 0, 0, 0, 5, 6, 6, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 8, 8, 7, 8, 8, 8, 8, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
All 464 samples without a truncating APC mutation (n = 411) and all samples with absent hMLH1 expression (n = 58) were analysed for mutations in the phosphorylation sites at codons 33, 37, 41 and 45 in exon 3 absent hMLH1 expression without a truncating APC mutation (n = 411) and all samples with absent hMLH1 expression (n = 58) were analysed for mutations in the phosphorylation sites at codons 33, 37, 41 and 45 in exon 3 of the CTNNB1 gene. This selection was made, since most mutations are expected in these samples. Tumours lacking truncating APC mutations may harbour CTNNB1 mutations [7], and microsatellite instable tumours are also expected to more frequently have mutations in CTNNB1 [26].
2275286-03-Methods-p03
[ "The", "sequences", "of", "primers", "and", "the", "fluorogenic", "probe", "were", "designed", "by", "MethPrimer", "software.", "Primer", "sequence", "for", "hMLH1", "was:", "CGTTATATATCGTTCGTAGTATTCGTGTTT(Forward),", "and", "CTATCGCCGCCTCATCGT", "(Reverse),", "probe", "sequence", "was", "6FAM-CGCGACGTCAAACGCCACTACG-TAMRA.", "For", "the", "MSP,", "5", "μL", "of", "bisulfite-converted", "DNA", "was", "used", "in", "each", "amplification.", "PCR", "was", "performed", "in", "a", "reaction", "volume", "of", "25", "μL", "consisting", "of", "5", "pmol", "of", "each", "primer,", "250", "pmol", "of", "probe,", "200", "μM", "each", "of", "dATP,", "dCTP,", "and", "dGTP,", "400", "μM", "dUTP,", "3.5", "mM", "MgCl2,", "1×", "TaqMan", "Buffer", "A,", "and", "2", "units", "of", "AmpliTaq", "Gold", "polymerase", "(Applied", "Biosystem", "Shanghai", "Division,", "Shanghai,", "China)", "at", "the", "following", "condition:", "95°C", "for", "10", "min,", "followed", "by", "50", "cycles", "at", "95°C", "for", "15", "s,", "and", "60°C", "for", "1", "min.", "All", "PCR", "was", "performed", "in", "the", "ABI-7000", "Real-Time", "PCR", "Detection", "system", "(Applied", "Biosystem", "Shanghai", "Division,", "Shanghai,", "China).", "CpGenomeTM", "Universal", "methylated", "DNA", "(Chemicon", "International", "Inc.,", "city,", "CA,", "USA)", "was", "included", "as", "positive", "control", "in", "all", "amplifications", "and", "glyceraldehyde-3-phosphate", "dehydrogenase", "(GAPDH)", "quantification", "of", "all", "untreated", "DNA", "was", "used", "as", "loading", "control." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The sequences of primers and the fluorogenic probe were designed by MethPrimer software. Primer sequence for hMLH1 was: CGTTATATATCGTTCGTAGTATTCGTGTTT(Forward), and CTATCGCCGCCTCATCGT (Reverse), probe sequence was 6FAM-CGCGACGTCAAACGCCACTACG-TAMRA. For the MSP, 5 μL of bisulfite-converted DNA was used in each amplification. PCR was performed in a reaction volume of 25 μL consisting of 5 pmol of each primer, 250 pmol of probe, 200 μM each of dATP, dCTP, and dGTP, 400 μM dUTP, 3.5 mM MgCl2, 1× TaqMan Buffer A, and 2 units of AmpliTaq Gold polymerase (Applied Biosystem Shanghai Division, Shanghai, China) at the following condition: 95°C for 10 min, followed by 50 cycles at 95°C for 15 s, and 60°C for 1 min. All PCR was performed in the ABI-7000 Real-Time PCR Detection system (Applied Biosystem Shanghai Division, Shanghai, China). CpGenomeTM Universal methylated DNA (Chemicon International Inc., city, CA, USA) was included as positive control in all amplifications and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) quantification of all untreated DNA was used as loading control.
1601966-03-Results-p03
[ "Individual", "chromosomal", "islands", "with", "gain", "of", "expression" ]
[ 0, 0, 0, 0, 0, 0, 0 ]
Individual chromosomal islands with gain of expression
2275286-04-Results-p02
[ "Clinical", "features", "of", "patients", "in", "MSI", "group", "with", "MMR", "gene", "mutations" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Clinical features of patients in MSI group with MMR gene mutations
3034663-05-Discussion-p02
[ "Nonetheless,", "we", "cannot", "exclude", "the", "possibility", "that", "this", "variant", "may", "result", "in", "a", "small", "increase", "in", "susceptibility", "to", "CRC", "or", "adenomas,", "as", "was", "suggested", "by", "Fearnhead", "et", "al", "[16].", "Further", "studies", "with", "appropriate", "sample", "sizes", "are", "required", "to", "address", "the", "low", "penetrance", "effect", "of", "this", "variant", "in", "CRC." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Nonetheless, we cannot exclude the possibility that this variant may result in a small increase in susceptibility to CRC or adenomas, as was suggested by Fearnhead et al [16]. Further studies with appropriate sample sizes are required to address the low penetrance effect of this variant in CRC.
1334229-01-Abstract-p01
[ "The", "early", "to", "intermediate", "stages", "of", "the", "majority", "of", "colorectal", "tumours", "are", "thought", "to", "be", "driven", "by", "aberrations", "in", "the", "Wnt", "(APC,", "CTNNB1)", "and", "Ras", "(K-ras)", "pathways.", "A", "smaller", "proportion", "of", "cancers", "shows", "mismatch", "repair", "deficiency.", "The", "aim", "of", "this", "study", "was", "to", "analyse", "the", "co-occurrence", "of", "these", "genetic", "alterations", "in", "relation", "to", "tumour", "and", "patient", "characteristics." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The early to intermediate stages of the majority of colorectal tumours are thought to be driven by aberrations in the Wnt (APC, CTNNB1) and Ras (K-ras) pathways. A smaller proportion of cancers shows mismatch repair deficiency. The aim of this study was to analyse the co-occurrence of these genetic alterations in relation to tumour and patient characteristics.
1334229-03-Methods-p01
[ "DNA", "isolation", "was", "described", "in", "detail", "elsewhere", "[27].", "Briefly,", "a", "4", "μm", "section,", "cut", "from", "each", "paraffin-embedded", "tumour", "tissue", "block,", "was", "stained", "with", "haematoxylin", "and", "eosin", "(HE)", "for", "histopathological", "examination", "by", "a", "pathologist.", "Five", "20", "μm", "sections", "of", "tumour", "tissue", "were", "cut", "from", "each", "sample", "for", "DNA", "isolation.", "Tumour", "tissue", "was", "separated", "from", "normal", "colon", "epithelium", "using", "the", "HE", "section", "as", "a", "reference.", "Genomic", "DNA", "was", "extracted", "from", "macrodissected", "tumour", "tissue", "using", "proteinase", "K", "(Qiagen,", "St.", "Louis,", "MO,", "USA)", "and", "the", "Puregene", "DNA", "isolation", "kit", "(Gentra", "Systems,", "Minneapolis,", "MN,", "USA).", "DNA", "concentration", "and", "purity", "was", "measured", "at", "260", "and", "280", "nm." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
DNA isolation was described in detail elsewhere [27]. Briefly, a 4 μm section, cut from each paraffin-embedded tumour tissue block, was stained with haematoxylin and eosin (HE) for histopathological examination by a pathologist. Five 20 μm sections of tumour tissue were cut from each sample for DNA isolation. Tumour tissue was separated from normal colon epithelium using the HE section as a reference. Genomic DNA was extracted from macrodissected tumour tissue using proteinase K (Qiagen, St. Louis, MO, USA) and the Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN, USA). DNA concentration and purity was measured at 260 and 280 nm.
1360090-03-Results-p01
[ "a", "Data", "was", "unavailable", "for", "MSI", "status", "in", "40", "cases,", "methylation", "status", "in", "83", "cases,", "KRAS", "mutation", "in", "26", "77", "BRAF", "1799T", "to", "A", "mutations", "BRAF", " ", "mutations", "in", "this", "CRC", "series,", "while", "Figure", "1B", "shows", "DNA", "sequencing", "confirmation", "of", "the", "1799T", "to", "A", "transversion", "resulting", "in", "the", "V600E", "mutation.", "The", "overall", "frequency", "of", "BRAF", "mutation", "was", "8.4%", "(23/275),", "comparing", "favourably", "with", "frequencies", "of", "9–11%", "reported", "for", "other", "large", "studies", "of", "this", "tumor", "type", "[6,16,17].", "The", "mean", "age", "of", "patients", "with", "and", "without", "BRAF", "mutation", "was", "identical", "(Table", "1).", "Strong", "associations", "were", "observed", "between", "BRAF", "mutation", "and", "tumor", "origin", "in", "the", "proximal", "side", "of", "the", "large", "bowel,", "poor", "histological", "grade,", "mucinous", "appearance", "and", "the", "presence", "of", "infiltrating", "lymphocytes.", "Higher", "frequencies", "of", "BRAF", "mutation", "were", "also", "observed", "in", "females", " ", "and", "in", "node", "negative", "tumors", "but", "these", "did", "not", "reach", "significance." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 11, 21, 5, 6, 6, 5, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 13, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
a Data was unavailable for MSI status in 40 cases, methylation status in 83 cases, KRAS mutation in 26 77 BRAF 1799T to A mutations BRAF mutations in this CRC series, while Figure 1B shows DNA sequencing confirmation of the 1799T to A transversion resulting in the V600E mutation. The overall frequency of BRAF mutation was 8.4% (23/275), comparing favourably with frequencies of 9–11% reported for other large studies of this tumor type [6,16,17]. The mean age of patients with and without BRAF mutation was identical (Table 1). Strong associations were observed between BRAF mutation and tumor origin in the proximal side of the large bowel, poor histological grade, mucinous appearance and the presence of infiltrating lymphocytes. Higher frequencies of BRAF mutation were also observed in females and in node negative tumors but these did not reach significance.
1360090-03-Results-p01
[ "a", "Data", "was", "unavailable", "for", "gender", "in", "43", "cases,", "infiltrating", "lymphocytes", "in", "55", "cases,", "nodal", "involvement", "in", "77", "cases,", "tumor", "site", "in", "56", "cases,", "grade", "in", "106", "cases", "and", "mucinous", "appearance", "in", "89", "cases." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
a Data was unavailable for gender in 43 cases, infiltrating lymphocytes in 55 cases, nodal involvement in 77 cases, tumor site in 56 cases, grade in 106 cases and mucinous appearance in 89 cases.
1619718-03-Materials-and-methods-p02
[ "This", "was", "undertaken", "on", "all", "adenomas", "and", "all", "serrated", "polyps", "with", "dysplasia", "(traditional", "SA", "and", "MP).", "Most", "of", "these", "polyps", "had", "been", "immunostained", "previously", "for", "MGMT.24", "Following", "deparaffinization", "and", "rehydration", "of", "4-µm", "sections", "and", "antigen", "retrieval", "using", "ethylene", "diamine", "tetra-acetic", "acid", "and", "microwaving,", "the", "sections", "were", "subjected", "to", "peroxidase", "blockade", "(Dako", "EnVision", "bottle", "1;", "Mississauga,", "Canada)", "and", "then", "incubated", "in", "10%", "goat", "serum", "to", "minimize", "non-specific", "staining.", "They", "were", "subsequently", "incubated", "with", "the", "primary", "anti-p53", "antibody", "(DO-7,", "from", "DakoCytomation,", "Mississauga,", "Canada)", "at", "a", "dilution", "of", "1", ":", "100", "for", "60", "min", "at", "37°C.", "After", "washing,", "the", "sections", "were", "incubated", "with", "secondary", "antibody", "(EnVision", "bottle", "2)", "for", "30", "min,", "washed", "again", "and", "then", "developed", "with", "the", "chromogen", "AEC", "for", "30", "min.", "Finally,", "the", "sections", "were", "counterstained", "with", "Gill's", "haematoxylin.", "Polyps", "were", "scored", "as", "showing", "loss", "of", "expression", "of", "MGMT", " ", "if", "there", "was", "complete", "absence", "of", "nuclear", "expression", "throughout", "one", "or", "more", "crypts.", "Polyps", "were", "scored", "as", "positive", "for", "aberrant", "p53", "mutation", " ", "analysis", "at", "codons", "12", "and", "13", "was", "performed", "using", "direct", "automated", "sequencing", "of", "a", "fragment", "containing", "codon", "12", "and", "13", "in", "exon", "1", "of", "the", "KRAS", "gene,", "amplified", "using", "a", "touchdown", "polymerase", "chain", "reaction", "(PCR)", "cycle", "and", "hotstart", "protocol.", "PCR", "products", "were", "initially", "purified", "and", "then", "directly", "sequenced", "using", "BigDye", "version", "3.1", "dye", "terminators", "and", "an", "ABI", "3100", "DNA", "fragment", "analyser.", "The", "sequence", "at", "codon", "12", "and", "13", "was", "determined", "using", "Mutation", "Surveyor", "(SoftGenetics,", "State", "College,", "PA,", "USA)", "software." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 7, 8, 8, 8, 8, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 5, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
This was undertaken on all adenomas and all serrated polyps with dysplasia (traditional SA and MP). Most of these polyps had been immunostained previously for MGMT.24 Following deparaffinization and rehydration of 4-µm sections and antigen retrieval using ethylene diamine tetra-acetic acid and microwaving, the sections were subjected to peroxidase blockade (Dako EnVision bottle 1; Mississauga, Canada) and then incubated in 10% goat serum to minimize non-specific staining. They were subsequently incubated with the primary anti-p53 antibody (DO-7, from DakoCytomation, Mississauga, Canada) at a dilution of 1 : 100 for 60 min at 37°C. After washing, the sections were incubated with secondary antibody (EnVision bottle 2) for 30 min, washed again and then developed with the chromogen AEC for 30 min. Finally, the sections were counterstained with Gill's haematoxylin. Polyps were scored as showing loss of expression of MGMT if there was complete absence of nuclear expression throughout one or more crypts. Polyps were scored as positive for aberrant p53 mutation analysis at codons 12 and 13 was performed using direct automated sequencing of a fragment containing codon 12 and 13 in exon 1 of the KRAS gene, amplified using a touchdown polymerase chain reaction (PCR) cycle and hotstart protocol. PCR products were initially purified and then directly sequenced using BigDye version 3.1 dye terminators and an ABI 3100 DNA fragment analyser. The sequence at codon 12 and 13 was determined using Mutation Surveyor (SoftGenetics, State College, PA, USA) software.
1334229-01-Abstract-p01
[ "Mutations", "at", "the", "phosphorylation", "sites", "(codons", "31,", "33,", "37,", "and", "45)", "in", "the", "CTNNB1", "gene", "were", "observed", "in", "tumours", "from", "only", "5/464", "patients.", "Tumours", "with", "truncating", "APC", "mutations", "and", "activating", "K-ras", "mutations", "in", "codons", "12", "and", "13", "occurred", "at", "similar", "frequencies", "(37%", "(245/656)", "and", "36%", "(235/656),", "respectively).", "Seventeen", "percent", "of", "tumours", "harboured", "both", "an", "APC", "and", "a", "K-ras", "mutation", "(109/656).", "Nine", "percent", "of", "all", "tumours", "(58/656)", "lacked", "hMLH1", "expression.", "Patients", "harbouring", "a", "tumour", "with", "absent", "hMLH1", "expression", "were", "older,", "more", "often", "women,", "more", "often", "had", "proximal", "colon", "tumours", "that", "showed", "poorer", "differentiation", "when", "compared", "to", "patients", "harbouring", "tumours", "colorectal", "cancer", "mismatch", "repair", "deficiency", ".", "The", "aim", "of", "this", "study", "was", "to", "analyse", "the", "co-occurrence", "of", "these", "genetic", "alterations", "in", "relation", "to", "tumour", "and", "patient", "characteristics." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 2, 7, 8, 8, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutations at the phosphorylation sites (codons 31, 33, 37, and 45) in the CTNNB1 gene were observed in tumours from only 5/464 patients. Tumours with truncating APC mutations and activating K-ras mutations in codons 12 and 13 occurred at similar frequencies (37% (245/656) and 36% (235/656), respectively). Seventeen percent of tumours harboured both an APC and a K-ras mutation (109/656). Nine percent of all tumours (58/656) lacked hMLH1 expression. Patients harbouring a tumour with absent hMLH1 expression were older, more often women, more often had proximal colon tumours that showed poorer differentiation when compared to patients harbouring tumours colorectal cancer mismatch repair deficiency . The aim of this study was to analyse the co-occurrence of these genetic alterations in relation to tumour and patient characteristics.
1334229-04-Results-p02
[ "Finally,", "to", "assess", "agreement", "between", "hMLH1", " ", "expression", "and", "microsatellite", "instability,", "both", "hMLH1", " ", "expression", "and", "BAT-26", "were", "analysed", "in", "162", "tumours.", "All", "tumours", "that", "had", "normal", "BAT-26,", "also", "showed", "hMLH1", "expression.", "Fourteen", "tumours", "with", "unstable", "BAT-26", "also", "lacked", "hMLH1", "expression,", "and", "two", "tumours", "with", "unstable", "BAT-26", "were", "found", "to", "express", "hMLH1", "unstable", "BAT-26", "tumours", "lacked", "hMLH1", "expression", "unstable", "BAT-26", "showed", "hMLH1", "expression", "tumours", ".", "All", "tumours", "that", "had", "normal", "BAT-26,", "also", "showed", "hMLH1", "expression.", "Fourteen", "tumours", "normal", "BAT-26", "hMLH1", " ", "deficiency,", "as", "determined", "by", "immunohistochemistry", "(Figure", "2).", "Tumours", "lacking", "hMLH1", "expression", "occur", "almost", "exclusively", "in", "the", "proximal", "colon", "(P", "<", "0.001)", "and", "relatively", "more", "frequently", "show", "poor", "differentiation", "or", "are", "undifferentiated", "(P", "<", "0.001)", "when", "compared", "to", "tumours", "with", "hMLH1", "hMLH1", " ", "expression", "occur", "almost", "exclusively", "in", "the", "proximal", "colon", "(P", "<", "0.001)", "and", "relatively", "more", "frequently", "show", "poor", "differentiation", "or", "are", "undifferentiated", "(P", "<", "0.001)", "when", "compared", "to", "tumours", "with", "hMLH1", "expression", "(Table", "3)." ]
[ 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 7, 8, 19, 20, 9, 7, 8, 8, 19, 20, 7, 8, 8, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 19, 20, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Finally, to assess agreement between hMLH1 expression and microsatellite instability, both hMLH1 expression and BAT-26 were analysed in 162 tumours. All tumours that had normal BAT-26, also showed hMLH1 expression. Fourteen tumours with unstable BAT-26 also lacked hMLH1 expression, and two tumours with unstable BAT-26 were found to express hMLH1 unstable BAT-26 tumours lacked hMLH1 expression unstable BAT-26 showed hMLH1 expression tumours . All tumours that had normal BAT-26, also showed hMLH1 expression. Fourteen tumours normal BAT-26 hMLH1 deficiency, as determined by immunohistochemistry (Figure 2). Tumours lacking hMLH1 expression occur almost exclusively in the proximal colon (P < 0.001) and relatively more frequently show poor differentiation or are undifferentiated (P < 0.001) when compared to tumours with hMLH1 hMLH1 expression occur almost exclusively in the proximal colon (P < 0.001) and relatively more frequently show poor differentiation or are undifferentiated (P < 0.001) when compared to tumours with hMLH1 expression (Table 3).
2386495-04-Results-p01
[ "Large", "deletions", "higher", "age", "at", "diagnosis", "cases", " ", "among", "the", "families", "was", "16%.", "In", "three", "of", "the", "families", "parents", "were", "tested", "negative", "for", "the", "mutation", "and", "in", "the", "remaining", "seven", "families", "we", "where", "unable", "to", "obtain", "samples", "to", "test", "parents.", "Thirty-two", "of", "the", "81", "patients", "with", "APC", "mutations", "were", "probands.", "Probands", "with", "mutations", "in", "the", "region", "from", "codon", "1250", "to", "1464", "of", "the", "APC", "gene", "which", "predicts", "a", "severe", "phenotype", "[36]", "had", "a", "median", "age", "at", "diagnosis", "of", "21.8", "(range,", "11–49)", "years", "compared", "with", "34.4", "(range,", "14–57)", "years", "among", "those", "with", "mutations", "outside", "this", "region", "(P", "<", "0.017).", "Available", "data", "on", "colorectal", "polyp", "number", "shows", "that,", "in", "spite", "of", "higher", "age", "at", "diagnosis,", "dense", "polyposis", "(>", "1000)", "only", "occurred", "in", "30%", "of", "the", "probands", "compared", "with", "75%", "in", "those", "with", "mutations", "between", "codon", "1250", "and", "1464.", "In", "the", "former", "group", "29%", "(7", "out", "of", "24)", "had", "CRC", "at", "diagnosis", "compared", "with", "25%", "(2", "out", "of", "8)", "in", "the", "latter", "group.", "The", "mean", "age", "at", "CRC", "was", "46.6", "(range", "28–57)", "and", "37.5", "(range", "26–49)", "years,", "respectively.", "The", "total", "morbidity", "in", "CRC", "among", "probands", "was", "34%", "(11", "out", "of", "32).", "Of", "all", "probands", "diagnosed", "after", "1996,", "four", "out", "of", "nine", "(", "44%", "APC", " ", "mutations,", "27", "novel", "and", "34", "recurrent,", "were", "detected", "among", "81", "of", "the", "96", "Swedish", "families", "studied", "as", "shown", "in", "Additional", "files", "1", "and", "2.", "A", "mutation", "spectrum", "displaying", "the", "distribution", "between", "novel", "and", "previously", "reported", "mutations", "is", "shown", "in", "Figure", "1.", "The", "frequency", "of", "APC", "de", "novo", "mutation", "cases", "among", "the", "families", "was", "16%.", "In", "three", "of", "the", "families", "parents", "were", "tested", "negative", "for", "the", "mutation", "and", "in", "the", "remaining", "seven", "families", "we", "where", "unable", "to", "obtain", "samples", "to", "test", "parents.", "Thirty-two", "of", "the", "81", "patients", "with", "APC", "APC", " ", "de", "novo", "mutation", "cases", "among", "the", "families", "was", "16%.", "In", "three", "of", "the", "families", "parents", "were", "tested", "negative", "for", "the", "mutation", "and", "in", "the", "remaining", "seven", "families", "we", "where", "unable", "to", "obtain", "samples", "to", "test", "parents.", "Thirty-two", "of", "the", "81", "patients", "with", "APC", "mutations", "were", "probands.", "Probands", "with", "mutations", "in", "the", "region", "from", "codon", "1250", "to", "1464", "of", "the", "APC", "gene", "which", "predicts", "a", "severe", "phenotype", "[36]", "had", "a", "median", "age", "at", "diagnosis", "of", "21.8", " ", "(range,", "11–49)", "years", "compared", "with", "34.4", "(range,", "14–57)", "years", "among", "those", "with", "mutations", "outside", "this", "region", "(P", "<", "0.017).", "Available", "data", "on", "colorectal", "polyp", "number", "shows", "that,", "in", "spite", "of", "higher", "age", "at", "diagnosis,", "dense", "polyposis", "(>", "1000)", "only", "occurred", "in", "30%", "of", "the", "probands", "compared", "with", "75%", "in", "those", "with", "mutations", "between", "codon", "1250", "and", "1464.", "In", "the", "former", "group", "29%", "(7", "out", "of", "24)", "had", "CRC", "at", "diagnosis", "compared", "with", "25%", "(2", "out", "of", "8)", "in", "the", "latter", "group.", "The", "mean", "age", "at", "CRC", " ", "was", "46.6", "(range", "28–57)", "and", "37.5", "(range", "26–49)", "years,", "respectively.", "The", "total", "morbidity", "in", "CRC", " ", "among", "probands", "was", "34%", "(11", "out", "of", "32).", "Of", "all", "probands", "diagnosed", "after", "1996,", "four", "out", "of", "nine", "(44%)", "had", "cancer", "at", "diagnosis.", "The", "median", "age", "in", "this", "group", "was", "47.5", "(range", "45–51)", "years", "and", "none", "had,", "despite", "high", "age", "at", "diagnosis", "of", "CRC", "patients", "Thirty-two", "of", "the", "81", " ", "patients", "with", "APC", "mutations", "were", "probands.", "Probands", "with", "mutations", "in", "the", "region", "from", "codon", "1250", "to", "1464", "of", "the", "APC", "gene", "which", "predicts", "a", "severe", "phenotype", "[36]", "had", "a", "median", "age", "at", "diagnosis", "of", "21.8", "(range,", "11–49)", "years", "compared", "with", "34.4", "(range,", "14–57)", "years", "among", "those", "with", "mutations", "outside", "this", "region", "(P", "<", "0.017).", "Available", "data", "on", "colorectal", "polyp", "number", "shows", "that,", "in", "spite", "of", "higher", "age", "at", "diagnosis,", "dense", "polyposis", "(>", "1000)", "only", "occurred", "in", "30%", "of", "the", "probands", "compared", "with", "75%", "in", "those", "with", "mutations", "between", "codon", "1250", "and", "1464.", "In", "the", "former", "group", "29%", "(7", "out", "of", "24)", "had", "CRC", "at", "diagnosis", "compared", "with", "25%", "(2", "out", "of", "8)", "in", "the", "latter", "group.", "The", "mean", "age", "at", "CRC", "was", "46.6", "(range", "28–57)", "and", "37.5", "(range", "26–49)", "years,", "respectively.", "The", "total", "morbidity", "in", "CRC", "among", "probands", "was", "34%", "(11", "out", "of", "32).", "Of", "all", "probands", "diagnosed", "after", "1996,", "four", "out", "of", "nine", "(44%)", "had", "cancer", "at", "diagnosis.", "The", "median", "age", "in", "this", "group", "was", "47.5", "(range", "45–51)", "years", "and", "none", "had,", "despite", "high", "age", "at", "diagnosis", "of", "CRC,", "dense", "colorectal", "polyposis", "at", "diagnosis", "indicating", "a", "less-severe", "phenotype.", "A", "compilation", "of", "clinical", "status", "of", "all", "patients", "dense", " ", "polyposis", "(>", "1000)", "only", "occurred", "in", "30%", "of", "the", "probands", "compared", "with", "75%", "in", "those", "with", "mutations", "between", "codon", "1250", "and", "1464.", "In", "the", "former", "group", "29%", "(7", "out", "of", "24)", "had", "CRC", "at", "diagnosis", "compared", "with", "25%", "(2", "out", "of", "8)", "in", "the", "latter", "group.", "The", "mean", "age", "at", "CRC", "was", "46.6", "(range", "28–57)", "and", "37.5", "(range", "26–49)", "years,", "respectively.", "The", "total", "morbidity", "in", "CRC", "among", "probands", "was", "34%", "(11", "out", "of", "32).", "Of", "all", "probands", "diagnosed", "after", "1996,", "four", "out", "of", "nine", "(44%)", "had", "cancer", "at", "diagnosis.", "The", "median", "age", "in", "this", "group", "was", "47.5", "(range", "45–51)", "years", "and", "none", "had,", "despite", "high", "age", "at", "diagnosis", "of", "CRC,", "dense", "colorectal", "polyposis", "at", "diagnosis", "indicating", "a", "less-severe", "phenotype", ".", "A", "compilation", "of", "clinical", "status", "of", "all", "patients", "analyzed", "in", "this", "study", "is", "shown", "in", "Additional", "file", "1." ]
[ 5, 6, 17, 18, 18, 18, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 15, 16, 16, 16, 16, 16, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 9, 11, 12, 12, 12, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 17, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 7, 8, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Large deletions higher age at diagnosis cases among the families was 16%. In three of the families parents were tested negative for the mutation and in the remaining seven families we where unable to obtain samples to test parents. Thirty-two of the 81 patients with APC mutations were probands. Probands with mutations in the region from codon 1250 to 1464 of the APC gene which predicts a severe phenotype [36] had a median age at diagnosis of 21.8 (range, 11–49) years compared with 34.4 (range, 14–57) years among those with mutations outside this region (P < 0.017). Available data on colorectal polyp number shows that, in spite of higher age at diagnosis, dense polyposis (> 1000) only occurred in 30% of the probands compared with 75% in those with mutations between codon 1250 and 1464. In the former group 29% (7 out of 24) had CRC at diagnosis compared with 25% (2 out of 8) in the latter group. The mean age at CRC was 46.6 (range 28–57) and 37.5 (range 26–49) years, respectively. The total morbidity in CRC among probands was 34% (11 out of 32). Of all probands diagnosed after 1996, four out of nine ( 44% APC mutations, 27 novel and 34 recurrent, were detected among 81 of the 96 Swedish families studied as shown in Additional files 1 and 2. A mutation spectrum displaying the distribution between novel and previously reported mutations is shown in Figure 1. The frequency of APC de novo mutation cases among the families was 16%. In three of the families parents were tested negative for the mutation and in the remaining seven families we where unable to obtain samples to test parents. Thirty-two of the 81 patients with APC APC de novo mutation cases among the families was 16%. In three of the families parents were tested negative for the mutation and in the remaining seven families we where unable to obtain samples to test parents. Thirty-two of the 81 patients with APC mutations were probands. Probands with mutations in the region from codon 1250 to 1464 of the APC gene which predicts a severe phenotype [36] had a median age at diagnosis of 21.8 (range, 11–49) years compared with 34.4 (range, 14–57) years among those with mutations outside this region (P < 0.017). Available data on colorectal polyp number shows that, in spite of higher age at diagnosis, dense polyposis (> 1000) only occurred in 30% of the probands compared with 75% in those with mutations between codon 1250 and 1464. In the former group 29% (7 out of 24) had CRC at diagnosis compared with 25% (2 out of 8) in the latter group. The mean age at CRC was 46.6 (range 28–57) and 37.5 (range 26–49) years, respectively. The total morbidity in CRC among probands was 34% (11 out of 32). Of all probands diagnosed after 1996, four out of nine (44%) had cancer at diagnosis. The median age in this group was 47.5 (range 45–51) years and none had, despite high age at diagnosis of CRC patients Thirty-two of the 81 patients with APC mutations were probands. Probands with mutations in the region from codon 1250 to 1464 of the APC gene which predicts a severe phenotype [36] had a median age at diagnosis of 21.8 (range, 11–49) years compared with 34.4 (range, 14–57) years among those with mutations outside this region (P < 0.017). Available data on colorectal polyp number shows that, in spite of higher age at diagnosis, dense polyposis (> 1000) only occurred in 30% of the probands compared with 75% in those with mutations between codon 1250 and 1464. In the former group 29% (7 out of 24) had CRC at diagnosis compared with 25% (2 out of 8) in the latter group. The mean age at CRC was 46.6 (range 28–57) and 37.5 (range 26–49) years, respectively. The total morbidity in CRC among probands was 34% (11 out of 32). Of all probands diagnosed after 1996, four out of nine (44%) had cancer at diagnosis. The median age in this group was 47.5 (range 45–51) years and none had, despite high age at diagnosis of CRC, dense colorectal polyposis at diagnosis indicating a less-severe phenotype. A compilation of clinical status of all patients dense polyposis (> 1000) only occurred in 30% of the probands compared with 75% in those with mutations between codon 1250 and 1464. In the former group 29% (7 out of 24) had CRC at diagnosis compared with 25% (2 out of 8) in the latter group. The mean age at CRC was 46.6 (range 28–57) and 37.5 (range 26–49) years, respectively. The total morbidity in CRC among probands was 34% (11 out of 32). Of all probands diagnosed after 1996, four out of nine (44%) had cancer at diagnosis. The median age in this group was 47.5 (range 45–51) years and none had, despite high age at diagnosis of CRC, dense colorectal polyposis at diagnosis indicating a less-severe phenotype . A compilation of clinical status of all patients analyzed in this study is shown in Additional file 1.
3034663-05-Discussion-p02
[ "The", "molecular", "hallmark", "of", "LS", "tumours", "is", "an", "MSI", "phenotype,", "a", "functional", "consequence", "of", "MMR", "deficiency.", "It", "is", "expected", "that", "the", "putative", "germ-line", "mutation", "responsible", "for", "LS", "would", "confer", "the", "MSI", "phenotype.", "We", "tested", "the", "MSI", "status", "of", "17", "tumours", "from", "p.Lys618Ala", "carriers", "and", "detected", "only", "two", "cases", "of", "MSI", "(11.8%).", "Taking", "into", "consideration", "the", "bias", "caused", "by", "the", "over-representation", "of", "Bethesda", "Criteria-positive", "tumours", "in", "this", "subset", "of", "cases", "(", "8/17", "tumours", " ", "in", "this", "subset", "of", "cases", "(8/17),", "the", "MSI", "frequency", "was", "not", "significantly", "different", "from", "that", "in", "the", "unselected", "CRC", "p.Lys618Ala", "tumours", " ", "from", "p.Lys618Ala", "carriers", "and", "detected", "only", "two", "cases", "of", "MSI", "(11.8%).", "Taking", "into", "consideration", "the", "bias", "caused", "by", "the", "over-representation", "of", "Bethesda", "Criteria-positive", "tumours", "in", "this", "subset", "of", "cases", "(8/17),", "the", "MSI", "frequency", "was", "not", "significantly", "different", "from", "that", "in", "the", "unselected", "CRC", "group", "[7].", "This", "is", "further", "proof", "that", "the", "presence", "of", "this", "variant", "is", "irrelevant", "to", "the", "functional", "inactivation", "of", "MLH1", "in", "CRC", " ", "patients." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 5, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0 ]
The molecular hallmark of LS tumours is an MSI phenotype, a functional consequence of MMR deficiency. It is expected that the putative germ-line mutation responsible for LS would confer the MSI phenotype. We tested the MSI status of 17 tumours from p.Lys618Ala carriers and detected only two cases of MSI (11.8%). Taking into consideration the bias caused by the over-representation of Bethesda Criteria-positive tumours in this subset of cases ( 8/17 tumours in this subset of cases (8/17), the MSI frequency was not significantly different from that in the unselected CRC p.Lys618Ala tumours from p.Lys618Ala carriers and detected only two cases of MSI (11.8%). Taking into consideration the bias caused by the over-representation of Bethesda Criteria-positive tumours in this subset of cases (8/17), the MSI frequency was not significantly different from that in the unselected CRC group [7]. This is further proof that the presence of this variant is irrelevant to the functional inactivation of MLH1 in CRC patients.
1334229-03-Methods-p01
[ "The", "PALGA", "reports", "were", "used", "to", "identify", "and", "locate", "tumour", "tissue", "from", "eligible", "colorectal", "cancer", "patients", "in", "Dutch", "pathology", "laboratories.", "Colon", "and", "rectal", "Dutch", "colorectal", "colorectal", " ", "cancer", "were", "identified", "within", "the", "cohort,", "of", "whom", "819", "could", "also", "be", "linked", "to", "a", "PALGA", "report", "of", "the", "lesion." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 25, 3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The PALGA reports were used to identify and locate tumour tissue from eligible colorectal cancer patients in Dutch pathology laboratories. Colon and rectal Dutch colorectal colorectal cancer were identified within the cohort, of whom 819 could also be linked to a PALGA report of the lesion.
1619718-04-Results-p01
[ "Frequency", "of", "KRAS", "and", "BRAF", "mutation", "and", "loss", "of", "expression", "of", "O-6-methylguanine", "DNA", "methyltransferase", "(MGMT)", "by", "polyp", "type" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Frequency of KRAS and BRAF mutation and loss of expression of O-6-methylguanine DNA methyltransferase (MGMT) by polyp type
1334229-03-Methods-p02
[ "All", "464", "samples", "without", "a", "truncating", "APC", "mutation", "(n", "=", "411)", "and", "all", "samples", "464", " ", "samples", "without", "a", "truncating", "APC", "mutation", "(n", "=", "411", ")", "and", "all", "samples", "with", "absent", "hMLH1", "expression", "(n", "=", "58)", "were", "analysed", "for", "mutations", "in", "the", "phosphorylation", "sites", "at", "codons", "33,", "37,", "41", "and", "45", "in", "exon", "3", "of", "the", "CTNNB1", "gene.", "This", "selection", "was", "made,", "since", "most", "mutations", "are", "expected", "in", "these", "samples.", "Tumours", "lacking", "truncating", "APC", "mutations", "737", " ", "patients,", "using", "nested", "PCR,", "followed", "by", "direct", "sequencing", "of", "purified", "fragments", "[27].", "The", "detection", "limit", "was", "5%", "mutated", "DNA", "and", "duplicate", "experiments", "revealed", "a", "good", "reproducibility", "(88%)", "[27]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
All 464 samples without a truncating APC mutation (n = 411) and all samples 464 samples without a truncating APC mutation (n = 411 ) and all samples with absent hMLH1 expression (n = 58) were analysed for mutations in the phosphorylation sites at codons 33, 37, 41 and 45 in exon 3 of the CTNNB1 gene. This selection was made, since most mutations are expected in these samples. Tumours lacking truncating APC mutations 737 patients, using nested PCR, followed by direct sequencing of purified fragments [27]. The detection limit was 5% mutated DNA and duplicate experiments revealed a good reproducibility (88%) [27].
3034663-04-Results-p01
[ "There", "were", "no", "significant", "associations", "in", "the", "case-control", "and", "case-case", "studies", "(80%", "detection", "power,", "OR", "=", "3.0;", "two-sided", "test,", "alpha", "level", "=", "5%)", "(Table", "2)", "and", "no", "statistically", "significant", "associations", "when", "the", "OR", "was", "adjusted", "for", "age", "and", "sex." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
There were no significant associations in the case-control and case-case studies (80% detection power, OR = 3.0; two-sided test, alpha level = 5%) (Table 2) and no statistically significant associations when the OR was adjusted for age and sex.
1266026-03-Methods-p01
[ "Quantitative", "analysis" ]
[ 0, 0 ]
Quantitative analysis
2386495-01-Abstract-p01
[ "Results" ]
[ 0 ]
Results
1619718-04-Results-p01
[ "Note:", "no", "result", "for", "KRAS", "in", "one", "sessile", "serrated", "adenoma", "(SSA)", "and", "one", "tubular", "adenoma", "(TA)", "or", "for", "BRAF", "in", "one", "TA.", "MGMT", "immunstaining", "not", "performed", "in", "15", "polyps", "(seven", "HPs,", "one", "SSA", "BRAF", " ", "and", "KRAS", "mutations", "were", "negatively", "correlated,", "with", "only", "four", "polyps", "having", "both", "mutations", "(two", "TAs,", "one", "TVA", "and", "one", "SSA).", "The", "three", "conventional", "adenomas", "with", "mutations", "of", "both", "BRAF", "and", "KRAS", "were", "among", "only", "four", "adenomas", "that", "had", "any", "BRAF", "mutations", "at", "all.", "Mutation", "frequencies", "for", "both", "KRAS", "and", "BRAF", "were", "distributed", "differently", "across", "the", "seven", "polyp", "groups", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Note: no result for KRAS in one sessile serrated adenoma (SSA) and one tubular adenoma (TA) or for BRAF in one TA. MGMT immunstaining not performed in 15 polyps (seven HPs, one SSA BRAF and KRAS mutations were negatively correlated, with only four polyps having both mutations (two TAs, one TVA and one SSA). The three conventional adenomas with mutations of both BRAF and KRAS were among only four adenomas that had any BRAF mutations at all. Mutation frequencies for both KRAS and BRAF were distributed differently across the seven polyp groups (Table 1).
1619718-01-Abstract-p01
[ "Conclusions" ]
[ 0 ]
Conclusions
1601966-03-Results-p08
[ "The", "region", "4p15.31-4p15.2", "is", "part", "of", "a", "larger", "region", "(see", "Table", "1)", "that", "showed", "marked", "down-regulation", "of", "expression", "in", "our", "tumor", "samples", "(see", "Figures", "21,", "22,", "23).", "Full", "or", "partial", "losses", "of", "chromosome", "4", "are", "well", "known", "phenomena", "in", "the", "development", "of", "CRC", "[18,19,23,24].", "One", "of", "the", "strongly", "down-regulated", "genes", "in", "this", "region", "is", "the", "SLIT2", "patient", " ", "counts", "with", "coordinate", "down-regulation).", "Grayscale", "plot", "of", "cross-comparison", "of", "down-regulation", "patterns", "across", "patients", "for", "gene", "pairs", "in", "a", "particular", "region.", "Both,", "horizontal", "and", "vertical", "axes", "comprise", "the", "same", "genes", "in", "chromosomal", "order.", "In", "each", "square", "total", "counts", "of", "patients", "with", "consistent", "down-regulation", "in", "two", "genes", "are", "coded", "by", "different", "shades", "of", "gray.", "Dark", "squared", "regions", "along", "the", "diagonal", "indicate", "coordinated", "regulation", "in", "patient", " ", "subgroups.", "Note,", "that", "many", "more", "patients", "show", "down-regulation", "as", "indicated", "by", "dark", "spots", "in", "this", "plot", "than", "up-regulation", "as", "indicated", "by", "dark", "spots", "in", "Figure", "10.", "This", "region", "has", "been", "reported", "in", "other", "studies", "to", "be", "frequently", "deleted", "in", "colorectal", "cancer", "(see", "Table", "4).", "This", "is", "the", "most", "significantly", "down-regulated", "region", "of", "our", "analysis.", "Note", "the", "expression", "of", "potential", "tumor", "genes", "PLA2G2A,", "E2F2,", "and", "CDC42." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The region 4p15.31-4p15.2 is part of a larger region (see Table 1) that showed marked down-regulation of expression in our tumor samples (see Figures 21, 22, 23). Full or partial losses of chromosome 4 are well known phenomena in the development of CRC [18,19,23,24]. One of the strongly down-regulated genes in this region is the SLIT2 patient counts with coordinate down-regulation). Grayscale plot of cross-comparison of down-regulation patterns across patients for gene pairs in a particular region. Both, horizontal and vertical axes comprise the same genes in chromosomal order. In each square total counts of patients with consistent down-regulation in two genes are coded by different shades of gray. Dark squared regions along the diagonal indicate coordinated regulation in patient subgroups. Note, that many more patients show down-regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 10. This region has been reported in other studies to be frequently deleted in colorectal cancer (see Table 4). This is the most significantly down-regulated region of our analysis. Note the expression of potential tumor genes PLA2G2A, E2F2, and CDC42.
1619718-04-Results-p01
[ "KRAS", "TAs", "TAs", "MP", "MP", "TVA", " ", "and", "one", "SSA).", "The", "three", "conventional", "adenomas", "with", "mutations", "of", "both", "BRAF", "and", "KRAS", "were", "among", "only", "four", "adenomas", "that", "had", "any", "BRAF", "mutations", "at", "all.", "Mutation", "frequencies", "for", "both", "KRAS", "and", "BRAF", "were", "distributed", "differently", "across", "the", "seven", "polyp", "groups", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
KRAS TAs TAs MP MP TVA and one SSA). The three conventional adenomas with mutations of both BRAF and KRAS were among only four adenomas that had any BRAF mutations at all. Mutation frequencies for both KRAS and BRAF were distributed differently across the seven polyp groups (Table 1).
3034663-05-Discussion-p02
[ "Herein,", "we", "describe", "the", "coexistence", "of", "the", "p.Lys618Ala", "variant", "with", "deleterious", "variants", "in", "another", "two", "unrelated", "LS", "families.", "In", "one", "family,", "the", "allele", "distribution", "of", "the", "pathogenic", "and", "unclassified", "variant", "was", "in", "trans,", "in", "the", "other", "family", "the", "pathogenic", "variant", "was", "detected", "in", "the", "MSH6", "gene", "and", "only", "the", "deleterious", "variant", "co-segregated", "with", "the", "disease", "in", "both", "families.", "This", "evidence", "indicates", "that", "the", "p.Lys618Ala", "variant", "is", "not", "deleterious." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Herein, we describe the coexistence of the p.Lys618Ala variant with deleterious variants in another two unrelated LS families. In one family, the allele distribution of the pathogenic and unclassified variant was in trans, in the other family the pathogenic variant was detected in the MSH6 gene and only the deleterious variant co-segregated with the disease in both families. This evidence indicates that the p.Lys618Ala variant is not deleterious.
1557864-01-Abstract-p01
[ "MSI", "was", "detected", "in", "three", "of", "the", "eight", "cell", "lines", "i.e.", "A2780", "(no", "MLH1", "mRNA", "expression", "due", "to", "promoter", "methylation),", "SKOV3", "(no", "MLH1", "mRNA", "expression)", "and", "2774", "(no", "altered", "expression", "of", "MMR", "genes).", "Overall,", "there", "was", "no", "association", "between", "cisplatin", "response", "and", "MMR", "status", "in", "these", "eight", "cell", "lines." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
MSI was detected in three of the eight cell lines i.e. A2780 (no MLH1 mRNA expression due to promoter methylation), SKOV3 (no MLH1 mRNA expression) and 2774 (no altered expression of MMR genes). Overall, there was no association between cisplatin response and MMR status in these eight cell lines.
1619718-05-Discussion-p05
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1360090-03-Results-p01
[ "Associations", "between", "BRAF", "mutation", "and", "molecular", "features", "of", "colorectal", "cancer." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Associations between BRAF mutation and molecular features of colorectal cancer.
1266026-05-Discussion-p01
[ "An", "epigenetic", "mechanism", "may", "help", "explain", "why", "sporadic", "MSI+", "cancers", "require", "more", "than", "one", "additional", "somatic", "alteration", "relative", "to", "HNPCC", "cancers.", "Inactivation", "of", "the", "normal", "MMR", "allele", "occurs", "through", "mutation", "(usually", "LOH", "[15])", "in", "HNPCC", "whereas", "MMR", "loss", "in", "sporadic", "MSI+", "cancers", "is", "associated", "with", "MLH1", "APC", " ", "and", "MMR", "loci)", "in", "both", "common", "colorectal", "familial", "cancer", "syndromes", "(FAP", "and", "HNPCC)", "appear", "to", "advance", "progression", "by", "more", "than", "a", "single", "mutation", "relative", "to", "their", "sporadic", "counterparts." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
An epigenetic mechanism may help explain why sporadic MSI+ cancers require more than one additional somatic alteration relative to HNPCC cancers. Inactivation of the normal MMR allele occurs through mutation (usually LOH [15]) in HNPCC whereas MMR loss in sporadic MSI+ cancers is associated with MLH1 APC and MMR loci) in both common colorectal familial cancer syndromes (FAP and HNPCC) appear to advance progression by more than a single mutation relative to their sporadic counterparts.
1334229-05-Discussion-p01
[ "The", "selection", "of", "patients", "included", "in", "this", "study", "was", "based", "on", "the", "completeness", "of", "analyses", "of", "both", "APC", "and", "K-ras", "genes", "as", "well", "as", "hMLH1", "expression", "and", "this", "led", "to", "a", "considerable", "reduction", "in", "the", "number", "of", "cases", "that", "could", "be", "included", "in", "the", "analyses", "presented", "in", "this", "study.", "The", "largest", "reduction", "(72", "cases)", "was", "due", "to", "incompleteness", "of", "the", "analysis", "of", "all", "fragments", "comprising", "the", "APC", "mutation", "cluster", "region.", "Tumour", "DNA", "was", "derived", "from", "formalin-fixed,", "paraffin-embedded", "tumour", "tissue", "blocks.", "Depending", "on", "the", "conditions", "of", "fixation", "and", "storage,", "the", "extracted", "DNA", "is", "more", "or", "less", "fragmented,", "which", "may", "have", "impaired", "the", "analysis", "of", "mutations", "in", "the", "APC", "gene", "more", "than", "in", "the", "K-ras", "gene,", "since", "the", "analysis", "of", "the", "latter", "is", "based", "on", "the", "amplification", "of", "a", "smaller", "gene", "fragment.", "It", "should", "be", "emphasized", "that", "characteristics", "of", "patients", "(age,", "sex,", "family", "history", "of", "colorectal", "cancer)", "and", "tumours", "(sub-localisation,", "Dukes'", "stage", "and", "differentiation)", "of", "the", "group", "under", "study", "are", "similar", "to", "the", "737", "patients", "for", "whom", "tumour", "material", "was", "available", "and", "to", "all", "819", "patients", "initially", "recognized", "within", "the", "cohort", "(data", "not", "shown).", "Moreover,", "the", "K-ras", "and", "hMLH1data", "presented", "here", "are", "similar", "to", "the", "data", "for", "K-ras", "and", "hMLH1", "based", "on", "the", "complete", "groups", "(737", "and", "724", "cases,", "respectively)", "(data", "not", "shown)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The selection of patients included in this study was based on the completeness of analyses of both APC and K-ras genes as well as hMLH1 expression and this led to a considerable reduction in the number of cases that could be included in the analyses presented in this study. The largest reduction (72 cases) was due to incompleteness of the analysis of all fragments comprising the APC mutation cluster region. Tumour DNA was derived from formalin-fixed, paraffin-embedded tumour tissue blocks. Depending on the conditions of fixation and storage, the extracted DNA is more or less fragmented, which may have impaired the analysis of mutations in the APC gene more than in the K-ras gene, since the analysis of the latter is based on the amplification of a smaller gene fragment. It should be emphasized that characteristics of patients (age, sex, family history of colorectal cancer) and tumours (sub-localisation, Dukes' stage and differentiation) of the group under study are similar to the 737 patients for whom tumour material was available and to all 819 patients initially recognized within the cohort (data not shown). Moreover, the K-ras and hMLH1data presented here are similar to the data for K-ras and hMLH1 based on the complete groups (737 and 724 cases, respectively) (data not shown).
1334229-03-Methods-p01
[ "Tumour", "material", "of", "colorectal", "cancer", " ", "patients", "was", "collected", "after", "approval", "by", "the", "Ethical", "Review", "Board", "of", "Maastricht", "University,", "PALGA", "and", "the", "NCR.", "Tissue", "samples", "from", "819", "colorectal", "cancer", "patients", "were", "localized", "in", "54", "pathology", "laboratories", "throughout", "the", "Netherlands.", "Forty-four", "rectal", "cancer", " ", "were", "classified", "according", "to", "site", "as", "follows,", "colon:", "cecum", "through", "sigmoid", "colon", "(ICD-O", "codes", "153.0,", "153.1,", "153.2,", "153.3,", "153.4,", "153.5,", "153.6,", "153.7),", "rectosigmoid", "(ICD-O", "code", "154.0),", "and", "rectum", "(ICD-O", "code", "154.1)." ]
[ 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 1, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Tumour material of colorectal cancer patients was collected after approval by the Ethical Review Board of Maastricht University, PALGA and the NCR. Tissue samples from 819 colorectal cancer patients were localized in 54 pathology laboratories throughout the Netherlands. Forty-four rectal cancer were classified according to site as follows, colon: cecum through sigmoid colon (ICD-O codes 153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7), rectosigmoid (ICD-O code 154.0), and rectum (ICD-O code 154.1).
1334229-02-Background-p01
[ "According", "to", "the", "paradigm", "for", "colorectal", "cancer", "development,", "mutations", "in", "the", "APC", "and", "K-ras", " ", "are", "thought", "to", "contribute", "to", "the", "early", "developmental", "stages", "of", "colorectal", "cancer", "[3].", "However,", "a", "recent", "study", "based", "on", "the", "analysis", "of", "APC,", "K-ras", " ", "and", "TP53", "genes", "concluded", "that", "simultaneous", "occurrence", "of", "all", "three", "genetic", "alterations", "is", "rare", "and", "that", "multiple", "genetic", "pathways", "may", "be", "relevant", "to", "colorectal", "cancer", "[9]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
According to the paradigm for colorectal cancer development, mutations in the APC and K-ras are thought to contribute to the early developmental stages of colorectal cancer [3]. However, a recent study based on the analysis of APC, K-ras and TP53 genes concluded that simultaneous occurrence of all three genetic alterations is rare and that multiple genetic pathways may be relevant to colorectal cancer [9].
1334229-03-Methods-p02
[ "Amplification", "of", "exon", "3", "of", "the", "CTNNB1", "gene", "entailed", "a", "semi-nested", "PCR", "strategy,", "which", "covered", "codons", "33,", "37,", "41", "and", "45.", "Flank", "PCR", "was", "performed", "to", "generate", "a", "308", "bp", "fragment", "(primers,", "forward:", "5'-CCAATCTACTAATGCTAATACTG-3',", "reverse:", "5'-GCATTCTGACTTTCAGTAAGGC-3')", "that", "was", "used", "in", "a", "1:100", "dilution", "for", "amplification", "of", "the", "final", "PCR", "product", "(primers,", "forward:", "5'-CCAATCTACTAATGCTAATACTG-3',", "reverse:", "5'-CTTCCTCAGGATTGCCTTTACC-3').", "In", "each", "PCR,", "one", "round", "of", "35", "cycles", "was", "performed." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Amplification of exon 3 of the CTNNB1 gene entailed a semi-nested PCR strategy, which covered codons 33, 37, 41 and 45. Flank PCR was performed to generate a 308 bp fragment (primers, forward: 5'-CCAATCTACTAATGCTAATACTG-3', reverse: 5'-GCATTCTGACTTTCAGTAAGGC-3') that was used in a 1:100 dilution for amplification of the final PCR product (primers, forward: 5'-CCAATCTACTAATGCTAATACTG-3', reverse: 5'-CTTCCTCAGGATTGCCTTTACC-3'). In each PCR, one round of 35 cycles was performed.
2386495-05-Discussion-p04
[ "Mutation-detection", "frequency" ]
[ 0, 0 ]
Mutation-detection frequency
1557864-05-Discussion-p02
[ "Since", "ovarian", "cancer", "is", "a", "heterogeneous", "disease", "characterized", "by", "various", "histological", "types", "which", "may", "have", "different", "MSI", "frequencies,", "the", "number", "of", "specimens", "analyzed", "is", "very", "important", "in", "characterizing", "a", "feature", "that", "may", "be", "uncommon", "such", "as", "MSI.", "We", "therefore,", "made", "a", "summary", "of", "20", "studies", "totaling", "1315", "ovarian", "carcinomas,", "to", "compare", "the", "findings", "of", "these", "studies", "with", "our", "results", "(Table", "2).", "The", "MSI", "frequencies", "determined", "in", "these", "studies", "ranged", "from", "0%", "to", "39%.", "Overall,", "MSI", "was", "detected", "in", "165", "of", "the", "1315", "1315", "carcinomas", "carcinomas", "carcinoma", "abundant", "methylation", "tumors", " ", "with", "low", "level", "MLH1", "promoter", "methylation", "appeared", "to", "express", "MLH1", "at", "mRNA", "levels", "similar", "to", "that", "of", "the", "unmethylated", "tumors.", "Thus", "a", "low", "level", "of", "methylation", "does", "not", "result", "in", "an", "altered", "expression", "of", "the", "MLH1", "gene.", "In", "contrast,", "the", "abundant", "methylation", "seen", "in", "the", "remaining", "carcinoma", "was", "associated", "with", "the", "lowest", "MLH1", "mRNA", "expression", "level", "of", "all", "50", "ovarian", "carcinomas", "tested.", "However,", "none", "of", "the", "ovarian", "carcinomas", "showed", "MSI", "for", "BAT25,", "BAT26", "and", "for", "BAT40", "or", "D2S123", "which", "suggests", "a", "frequency", "of", "MMR", "low", "level", "MLH1", "promoter", "methylation", "tumors", "75", " ", "ovarian", "carcinomas", "to", "determine", "the", "frequency", "of", "MMR", "inactivation", "in", "ovarian", "cancer", "in", "vivo.", "Seven", "of", "the", "75", "ovarian", "carcinomas", "showed", "MLH1", "promoter", "methylation.", "We", "confirmed", "whether", "the", "observed", "MLH1", "promoter", "methylation", "results", "in", "the", "inactivation", "of", "the", "gene", "by", "determining", "the", "MLH1", "mRNA", "expression", "with", "quantitative", "RT-PCR.", "The", "six", "tumors", "with", "low", "level", "MLH1", "promoter", "methylation", "appeared", "to", "express", "MLH1", " ", "at", "mRNA", "levels", "similar", "to", "that", "of", "the", "unmethylated", "tumors.", "Thus", "a", "low", "level", "of", "methylation", "does", "not", "result", "in", "an", "altered", "expression", "of", "the", "MLH1", " ", "gene.", "In", "contrast,", "the", "abundant", "methylation", "seen", "in", "the", "remaining", "carcinoma", "was", "associated", "with", "the", "lowest", "MLH1", "mRNA", "expression", "level", "of", "all", "50", "ovarian", "carcinomas", "tested.", "However,", "none", "of", "the", "ovarian", "carcinomas", "showed", "MSI", "for", "BAT25,", "BAT26", "and", "for", "BAT40", "or", "D2S123", "which", "suggests", "a", "frequency", "of", "MMR", "inactivation", "of", "0%.", "The", "low", "MLH1", "mRNA", "expression", "seen", "in", "the", "abundant", "methylated", "carcinoma", "might", "be", "sufficient", "enough", "for", "a", "functional", "MMR", "which", "results", "in", "the", "observed", "absence", "of", "MSI." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 12, 12, 12, 11, 9, 1, 1, 7, 8, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 7, 8, 8, 8, 8, 9, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Since ovarian cancer is a heterogeneous disease characterized by various histological types which may have different MSI frequencies, the number of specimens analyzed is very important in characterizing a feature that may be uncommon such as MSI. We therefore, made a summary of 20 studies totaling 1315 ovarian carcinomas, to compare the findings of these studies with our results (Table 2). The MSI frequencies determined in these studies ranged from 0% to 39%. Overall, MSI was detected in 165 of the 1315 1315 carcinomas carcinomas carcinoma abundant methylation tumors with low level MLH1 promoter methylation appeared to express MLH1 at mRNA levels similar to that of the unmethylated tumors. Thus a low level of methylation does not result in an altered expression of the MLH1 gene. In contrast, the abundant methylation seen in the remaining carcinoma was associated with the lowest MLH1 mRNA expression level of all 50 ovarian carcinomas tested. However, none of the ovarian carcinomas showed MSI for BAT25, BAT26 and for BAT40 or D2S123 which suggests a frequency of MMR low level MLH1 promoter methylation tumors 75 ovarian carcinomas to determine the frequency of MMR inactivation in ovarian cancer in vivo. Seven of the 75 ovarian carcinomas showed MLH1 promoter methylation. We confirmed whether the observed MLH1 promoter methylation results in the inactivation of the gene by determining the MLH1 mRNA expression with quantitative RT-PCR. The six tumors with low level MLH1 promoter methylation appeared to express MLH1 at mRNA levels similar to that of the unmethylated tumors. Thus a low level of methylation does not result in an altered expression of the MLH1 gene. In contrast, the abundant methylation seen in the remaining carcinoma was associated with the lowest MLH1 mRNA expression level of all 50 ovarian carcinomas tested. However, none of the ovarian carcinomas showed MSI for BAT25, BAT26 and for BAT40 or D2S123 which suggests a frequency of MMR inactivation of 0%. The low MLH1 mRNA expression seen in the abundant methylated carcinoma might be sufficient enough for a functional MMR which results in the observed absence of MSI.
1619718-05-Discussion-p02
[ "Serrated", "polyps", "with", "dysplasia,", "i.e.", "MPs", "and", "SAs,", "together", "comprised", "only", "2%", "of", "the", "overall", "consecutive", "series", "of", "1250", "polyps.", "While", "mutation", "of", "KRAS", "and", "BRAF", "was", "associated", "with", "conventional", "adenoma", "and", "SSA,", "respectively", "(see", "above),", "BRAF", "and", "KRAS", "mutation", "occurred", "with", "similar", "frequency", "in", "both", "MPs", "(40%", "and", "50%,", "respectively)", "and", "SAs", "(33%", "and", "27%,", "respectively).", "In", "the", "literature,", "the", "frequency", "of", "BRAF", "and", "KRAS", "mutation", "in", "MP", "or", "SA", "has", "ranged", "from", "36", "to", "100%", "and", "from", "0%", "to", "60%,", "respectively.12,16,39–42", "These", "findings", "indicate", "that", "this", "subset", "of", "colorectal", "polyps", "is", "likely", "to", "be", "heterogeneous", "in", "terms", "of", "its", "molecular", "origins.", "These", "polyps", "were", "therefore", "reclassified", "according", "to", "their", "resemblance", "to", "HP", "or", "SSA", "(Group", "A)", "(Figure", "1A,B,E,F)", "or", "to", "conventional", "adenoma", "adenoma", "rectum", "Non-dysplastic", " ", "serrated", " ", "polyps", ":", "HP", " ", "and", "SSA" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 3, 19, 0, 17, 0, 1, 0, 1, 0, 0, 0 ]
Serrated polyps with dysplasia, i.e. MPs and SAs, together comprised only 2% of the overall consecutive series of 1250 polyps. While mutation of KRAS and BRAF was associated with conventional adenoma and SSA, respectively (see above), BRAF and KRAS mutation occurred with similar frequency in both MPs (40% and 50%, respectively) and SAs (33% and 27%, respectively). In the literature, the frequency of BRAF and KRAS mutation in MP or SA has ranged from 36 to 100% and from 0% to 60%, respectively.12,16,39–42 These findings indicate that this subset of colorectal polyps is likely to be heterogeneous in terms of its molecular origins. These polyps were therefore reclassified according to their resemblance to HP or SSA (Group A) (Figure 1A,B,E,F) or to conventional adenoma adenoma rectum Non-dysplastic serrated polyps : HP and SSA
2386495-03-Methods-p01
[ "Patients", "without", "any", "detected", "mutation", "in", "APC", "or", "MUTYH" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Patients without any detected mutation in APC or MUTYH
3034663-03-Methods-p01
[ "We", "genotyped", "the", "p.Lys618Ala", "variant", "in", "MLH1", "in", "1034", "individuals", "(373", "sporadic", "CRC", "patients,", "250", "index", "subjects", "from", "families", "suspected", "of", "having", "LS", "[revised", "Bethesda", "Guidelines]", "and", "411", "controls).", "The", "controls", "were", "selected", "from", "the", "same", "hospitals,", "had", "no", "personal", "histories", "of", "cancer", "and", "had", "diagnoses", "unrelated", "to", "the", "variables", "of", "interest.", "They", "were", "matched", "for", "age,", "gender", "and", "race/ethnicity", "with", "the", "sporadic", "CRC", "patients." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
We genotyped the p.Lys618Ala variant in MLH1 in 1034 individuals (373 sporadic CRC patients, 250 index subjects from families suspected of having LS [revised Bethesda Guidelines] and 411 controls). The controls were selected from the same hospitals, had no personal histories of cancer and had diagnoses unrelated to the variables of interest. They were matched for age, gender and race/ethnicity with the sporadic CRC patients.
1334229-04-Results-p01
[ "Of", "656", "tumours", "for", "which", "the", "other", "molecular", "alterations,", "i.e.", "mutations", "in", "the", "APC", " ", "and", "K-ras", "genes", "and", "hMLH1", "expression,", "were", "all", "successfully", "and", "completely", "analysed,", "103", "colorectal", "tumours", "did", "not", "harbour", "a", "truncating", "or", "missense", "APC", "mutation,", "an", "activating", "K-ras", "mutation", "or", "showed", "lack", "of", "hMLH1", "expression,", "as", "depicted", "in", "figure", "1.", "Truncating", "as", "well", "as", "missense", "APC", "mutations", "and", "activating", "K-ras", "mutations", "were", "relatively", "common.", "Truncating", "APC", "mutations", "alone", "and", "activating", "K-ras", "mutations", "in", "codons", "12", "and", "13", "only,", "occurred", "at", "similar", "frequencies", "(20%", "(130/656)", "and", "18%", "(121/656),", "respectively).", "A", "combination", "of", "a", "truncating", "mutation", "in", "APC", "and", "an", "activating", "mutation", "in", "K-ras", "occurred", "less", "often", "than", "the", "sole", "occurrences", "of", "mutations", "in", "both", "genes.", "However,", "as", "shown", "in", "table", "2,", "the", "simultaneous", "occurrence", "of", "mutations", "in", "both", "genes", "occurred", "more", "frequently", "than", "expected", "on", "the", "basis", "of", "chance", "alone.", "A", "χ2", "test", "for", "the", "occurrence", "of", "a", "truncating", "APC", "mutation", "and", "an", "activating", "K-ras", "mutation", "truncating", "APC", "mutation", "mutation", " ", "in", "the", "CTNNB1", "gene,", "that", "did", "not", "occur", "at", "the", "Ser/Thr", "phosphorylation", "sites,", "but", "would", "result", "in", "an", "amino", "acid", "alteration", "at", "codons", "22", "and", "29,", "the", "effects", "of", "which", "are", "unknown.", "Because", "of", "the", "very", "low", "frequency", "of", "tumours", "harbouring", "a", "CTNNB1", "mutation,", "these", "mutations", "were", "not", "included", "in", "further", "analyses.", "In", "addition,", "mutation", "analysis", "of", "remaining", "samples", "was", "abandoned,", "since", "this", "was", "deemed", "irrelevant", "as", "these", "harboured", "truncating", "APC", "mutations", "and", "are", "considered", "to", "be", "unlikely", "to", "also", "have", "CTNNB1", "mutations", "[7]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 6, 5, 6, 6, 5, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Of 656 tumours for which the other molecular alterations, i.e. mutations in the APC and K-ras genes and hMLH1 expression, were all successfully and completely analysed, 103 colorectal tumours did not harbour a truncating or missense APC mutation, an activating K-ras mutation or showed lack of hMLH1 expression, as depicted in figure 1. Truncating as well as missense APC mutations and activating K-ras mutations were relatively common. Truncating APC mutations alone and activating K-ras mutations in codons 12 and 13 only, occurred at similar frequencies (20% (130/656) and 18% (121/656), respectively). A combination of a truncating mutation in APC and an activating mutation in K-ras occurred less often than the sole occurrences of mutations in both genes. However, as shown in table 2, the simultaneous occurrence of mutations in both genes occurred more frequently than expected on the basis of chance alone. A χ2 test for the occurrence of a truncating APC mutation and an activating K-ras mutation truncating APC mutation mutation in the CTNNB1 gene, that did not occur at the Ser/Thr phosphorylation sites, but would result in an amino acid alteration at codons 22 and 29, the effects of which are unknown. Because of the very low frequency of tumours harbouring a CTNNB1 mutation, these mutations were not included in further analyses. In addition, mutation analysis of remaining samples was abandoned, since this was deemed irrelevant as these harboured truncating APC mutations and are considered to be unlikely to also have CTNNB1 mutations [7].
1619718-04-Results-p01
[ "Mutation", "frequencies", "for", "both", "KRAS", "(P", "<", "0.0001)", "and", "BRAF", "(P", "<", "0.0001)", "are", "distributed", "differently", "across", "the", "seven", "classes", "of", "polyp", "(see", "Results", "for", "individual", "comparisons).", "Distribution", "of", "MGMT", "loss", "differs", "across", "the", "seven", "classes", "of", "polyp", "(P", "<", "0.001)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutation frequencies for both KRAS (P < 0.0001) and BRAF (P < 0.0001) are distributed differently across the seven classes of polyp (see Results for individual comparisons). Distribution of MGMT loss differs across the seven classes of polyp (P < 0.001).
1266026-03-Methods-p01
[ "Numbers", "of", "oncogenic", "alterations", "(genetic", "mutations", "or", "epigenetic", "alterations)", "required", "for", "transformation", "were", "estimated", "from", "ages", "at", "cancer", "using", "a", "Bayesian", "approach", "as", "previously", "described", "[11].", "This", "method", "requires", "the", "use", "of", "a", "life", "table", "from", "census", "data:", "for", "the", "Finnish", "data", "set", "we", "used", "a", "Finnish", "life", "table", "from", "the", "World", "Health", "Organization", "website", ",", "for", "the", "SEER", "dataset", "we", "used", "a", "United", "States", "life", "table", "as", "described", "previously", "[11].", "The", "model", "assumes", "the", "first", "visible", "clonal", "expansion", "occurs", "at", "the", "time", "of", "transformation", "and", "ignores", "the", "interval", "after", "transformation.", "The", "analysis", "ignores", "temporal", "trends,", "which", "may", "influence", "our", "mutation", "estimates." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Numbers of oncogenic alterations (genetic mutations or epigenetic alterations) required for transformation were estimated from ages at cancer using a Bayesian approach as previously described [11]. This method requires the use of a life table from census data: for the Finnish data set we used a Finnish life table from the World Health Organization website , for the SEER dataset we used a United States life table as described previously [11]. The model assumes the first visible clonal expansion occurs at the time of transformation and ignores the interval after transformation. The analysis ignores temporal trends, which may influence our mutation estimates.
1619718-05-Discussion-p04
[ "Loss", "of", "expression", "of", "the", "DNA", "repair", "gene", "MGMT", "is", "associated", "with", "methylation", "of", "the", "promoter", "region45,51,52", "and", "the", "latter", "change", "has", "been", "linked", "causatively", "with", "G:C", "to", "A:T", "transition", "mutations", "in", "TP53.53", "In", "the", "present", "study,", "complete", "or", "partial", "loss", "of", "expression", "of", "MGMT", "coincided", "with", "aberrant", "nuclear", "expression", "of", "p53", "in", "three", "serrated", "polyps", "with", "dysplasia", "(Figure", "2),", "but", "not", "in", "the", "single", "tubular", "adenoma", "with", "aberrant", "p53", "expression.", "Only", "one", "previous", "study", "has", "attempted", "to", "correlate", "MGMT", "and", "p53", "expression", "in", "colorectal", "polyps.45", "In", "that", "study,", "4.3%", "of", "adenomas", "showed", "aberrant", "p53", "expression", "but", "none", "had", "loss", "of", "MGMT.", "It", "is", "possible", "that", "the", "link", "between", "MGMT", "silencing", "and", "TP53", "mutation", "is", "more", "evident", "in", "the", "serrated", "pathway", "than", "in", "the", "adenoma–carcinoma", "sequence.", "The", "frequency", "of", "TP53", "mutation", "in", "SAs", "has", "ranged", "from", "5", "to", "50%", "in", "the", "literature.39,41,54", "Although", "a", "link", "between", "MGMT", "loss", "and", "aberrant", "expression", "of", "p53", "is", "supported", "by", "the", "present", "findings,", "it", "should", "be", "noted", "that", "only", "a", "small", "number", "of", "polyps", "showed", "these", "changes", "concurrently." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Loss of expression of the DNA repair gene MGMT is associated with methylation of the promoter region45,51,52 and the latter change has been linked causatively with G:C to A:T transition mutations in TP53.53 In the present study, complete or partial loss of expression of MGMT coincided with aberrant nuclear expression of p53 in three serrated polyps with dysplasia (Figure 2), but not in the single tubular adenoma with aberrant p53 expression. Only one previous study has attempted to correlate MGMT and p53 expression in colorectal polyps.45 In that study, 4.3% of adenomas showed aberrant p53 expression but none had loss of MGMT. It is possible that the link between MGMT silencing and TP53 mutation is more evident in the serrated pathway than in the adenoma–carcinoma sequence. The frequency of TP53 mutation in SAs has ranged from 5 to 50% in the literature.39,41,54 Although a link between MGMT loss and aberrant expression of p53 is supported by the present findings, it should be noted that only a small number of polyps showed these changes concurrently.
1360090-04-Discussion-p01
[]
[]
1334229-02-Background-p01
[ "According", "to", "the", "paradigm", "for", "colorectal", "cancer", "development,", "mutations", "in", "the", "APC", "and", "K-ras", "are", "thought", "to", "contribute", "to", "the", "early", "developmental", "stages", "of", "colorectal", "cancer", "[3].", "However,", "a", "recent", "study", "based", "on", "the", "analysis", "of", "APC,", "K-ras", "and", "TP53", "genes", "concluded", "that", "simultaneous", "occurrence", "of", "all", "three", "genetic", "alterations", "is", "rare", "and", "that", "multiple", "genetic", "pathways", "may", "be", "relevant", "to", "colorectal", "cancer", "[9]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
According to the paradigm for colorectal cancer development, mutations in the APC and K-ras are thought to contribute to the early developmental stages of colorectal cancer [3]. However, a recent study based on the analysis of APC, K-ras and TP53 genes concluded that simultaneous occurrence of all three genetic alterations is rare and that multiple genetic pathways may be relevant to colorectal cancer [9].
1557864-02-Background-p01
[ "Inactivation", "of", "MMR", "leads", "to", "the", "occurrence", "of", "unrepaired", "deletions", "in", "mono-", "and", "dinucleotide", "repeats", "resulting", "in", "variable", "lengths", "of", "these", "repeats.", "This", "is", "called", "microsatellite", "instability", "(MSI)", "and", "MSI", "is", "therefore", "used", "as", "a", "marker", "for", "MMR", "deficiency.", "MSI", "can", "be", "caused", "by", "genetic", "or", "epigenetic", "inactivation", "of", "several", "genes", "involved", "in", "MMR.", "Mouse", "knockout", "models", "have", "demonstrated", "that", "MSH2-/-,", "MSH3-/-,", "MLH1", "-/-", "MSH3", " ", "dimer", "(hMutSβ", "complex)", "recognizes", "insertion/deletion", "loops", "of", "more", "then", "one", "base.", "After", "the", "recognition", "of", "the", "DNA", "damage", "the", "binding", "of", "a", "heterodimer", "of", "the", "MutS-homologs", "MLH1", "and", "PMS2", "(the", "hMutLα", "complex)", "leads", "to", "the", "further", "initiation", "of", "MMR.", "Other", "known", "and", "still", "unknown", "proteins", "involved", "in", "the", "last", "two", "steps", "of", "MMR,", "the", "excision", "of", "the", "damaged", "strand", "and", "the", "resynthesis,", "are", "recruited", "subsequently.", "Proteins", "known", "to", "be", "involved", "are", "exonuclease", "ExoI,", "proliferating", "cell", "nuclear", "antigen", "(PCNA),", "DNA", "polymerase", "δ", "and", "perhaps", "ε", "and", "in", "addition", "based", "on", "its", "association", "with", "DNA", "polymerase", "δ", "and", "PCNA,", "DNA", "ligase", "I", "[8,9]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Inactivation of MMR leads to the occurrence of unrepaired deletions in mono- and dinucleotide repeats resulting in variable lengths of these repeats. This is called microsatellite instability (MSI) and MSI is therefore used as a marker for MMR deficiency. MSI can be caused by genetic or epigenetic inactivation of several genes involved in MMR. Mouse knockout models have demonstrated that MSH2-/-, MSH3-/-, MLH1 -/- MSH3 dimer (hMutSβ complex) recognizes insertion/deletion loops of more then one base. After the recognition of the DNA damage the binding of a heterodimer of the MutS-homologs MLH1 and PMS2 (the hMutLα complex) leads to the further initiation of MMR. Other known and still unknown proteins involved in the last two steps of MMR, the excision of the damaged strand and the resynthesis, are recruited subsequently. Proteins known to be involved are exonuclease ExoI, proliferating cell nuclear antigen (PCNA), DNA polymerase δ and perhaps ε and in addition based on its association with DNA polymerase δ and PCNA, DNA ligase I [8,9].
1557864-05-Discussion-p01
[ "Next", "we", "studied", "the", "association", "between", "MMR", "inactivation", "and", "cisplatin", "resistance", "in", "these", "cell", "lines.", "MMR", "inactivation", "seen", "in", "SKOV3", "and", "2774", "might", "result", "in", "the", "relative", "resistance", "to", "cisplatin", "compared", "to", "the", "other", "cell", "lines.", "On", "the", "other", "hand,", "A2780", "which", "has", "clearly", "an", "inactive", "MMR,", "was", "most", "sensitive", "to", "cisplatin.", "Overall,", "there", "seems", "to", "be", "no", "association", "between", "the", "response", "to", "cisplatin", "and", "MMR", "status", "in", "these", "eight", "SKOV3", ",", "2774,", "OVCAR3,", "KB3.1,", "CAOV3", "and", "A2780.", "Microsatellite", "instability", "(MSI),", "which", "is", "a", "marker", "for", "MMR", "inactivation,", "was", "detected", "in", "three", "out", "of", "eight", "cell", "lines", "i.e.", "SKOV3,", "2774", "and", "A2780.", "This", "results", "in", "a", "frequency", "of", "MMR", "inactivation", "in", "ovarian", "cancer", "cell", "lines", "of", "38%.", "The", "MSI", "in", "SKOV3", "can", "be", "explained", "by", "the", "loss", "of", "MLH1", "mRNA", "expression", "which,", "however,", "was", "not", "caused", "by", "promoter", "methylation.", "This", "is", "in", "agreement", "with", "the", "loss", "of", "MLH1", "protein", "expression", "seen", "in", "SKOV3", "described", "in", "a", "study", "of", "the", "60", "NCI", "cancer", "cell", "lines", "[44].", "In", "concordance", "with", "our", "findings,", "2774", "was", "also", "described", "to", "be", "MSI", "[45].", "One", "of", "the", "MSI", "positive", "A2780", "sublines", "showed", "a", "strong", "methylation", "of", "the", "MLH1", "promoter", "without", "MLH1", "mRNA", "expression,", "while", "the", "other", "subline", "showed", "a", "low", "level", "of", "methylation", "and", "relative", "high", "mRNA", "expression.", "Strathdee", "et", "al.", "described", "that", "one", "MLH1", "allele", "was", "methylated", "in", "A2780", "[12]", "which", "is", "comparable", "with", "the", "methylation", "status", "we", "saw", "in", "A2780,", "moreover", "one", "of", "our", "A2780", "sublines", "showed", "complete", "methylation.", "On", "the", "other", "hand,", "another", "study", "did", "not", "detect", "MSI", "in", "A2780", "[11].", "Interestingly,", "Aquilina", "and", "colleagues", "suggested", "there", "is", "a", "subpopulation", "of", "A2780", "cells,", "estimated", "to", "be", "around", "one", "per", "106", "cells", "[46],", "which", "are", "MLH1", "deficient", "and", "heterozygous", "for", "the", "p53phe172", "mutation", "[46,47].", "Since", "these", "cells", "have", "a", "growth", "advantage,", "prolonged", "culturing", "of", "the", "A2780", "cell", "line", "can", "result", "in", "selection", "of", "this", "subpopulation.", "Thus", "over", "time,", "separately", "cultured", "A2780", "can", "have", "varying", "percentages", "of", "cells", "belonging", "to", "this", "subpopulation", "which", "may", "explain", "the", "discrepancies", "in", "MMR", "status", "seen", "in", "the", "A2780", "cell", "lines", "analyzed", "by", "us." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Next we studied the association between MMR inactivation and cisplatin resistance in these cell lines. MMR inactivation seen in SKOV3 and 2774 might result in the relative resistance to cisplatin compared to the other cell lines. On the other hand, A2780 which has clearly an inactive MMR, was most sensitive to cisplatin. Overall, there seems to be no association between the response to cisplatin and MMR status in these eight SKOV3 , 2774, OVCAR3, KB3.1, CAOV3 and A2780. Microsatellite instability (MSI), which is a marker for MMR inactivation, was detected in three out of eight cell lines i.e. SKOV3, 2774 and A2780. This results in a frequency of MMR inactivation in ovarian cancer cell lines of 38%. The MSI in SKOV3 can be explained by the loss of MLH1 mRNA expression which, however, was not caused by promoter methylation. This is in agreement with the loss of MLH1 protein expression seen in SKOV3 described in a study of the 60 NCI cancer cell lines [44]. In concordance with our findings, 2774 was also described to be MSI [45]. One of the MSI positive A2780 sublines showed a strong methylation of the MLH1 promoter without MLH1 mRNA expression, while the other subline showed a low level of methylation and relative high mRNA expression. Strathdee et al. described that one MLH1 allele was methylated in A2780 [12] which is comparable with the methylation status we saw in A2780, moreover one of our A2780 sublines showed complete methylation. On the other hand, another study did not detect MSI in A2780 [11]. Interestingly, Aquilina and colleagues suggested there is a subpopulation of A2780 cells, estimated to be around one per 106 cells [46], which are MLH1 deficient and heterozygous for the p53phe172 mutation [46,47]. Since these cells have a growth advantage, prolonged culturing of the A2780 cell line can result in selection of this subpopulation. Thus over time, separately cultured A2780 can have varying percentages of cells belonging to this subpopulation which may explain the discrepancies in MMR status seen in the A2780 cell lines analyzed by us.
3034663-04-Results-p01
[ "In", "the", "second", "LS", "family,", "the", "index", "subject,", "one", "sister", "and", "one", "brother", "with", "CRC", "(II-5;", "II-6;", "II-7,", "respectively)", "had", "a", "deleterious", "variant", "in", "MSH6", "(c.3013C>T;", "p.Arg1005X)", "but", "did", "not", "have", "the", "p.Lys618Ala", "variant.", "This", "variant", "was", "present", "in", "only", "three", "of", "four", "unaffected", "nephews", "(III-2;", "III-3;", "III-4)", "and", "was", "inherited", "from", "the", "parental", "branch,", "in", "which", "there", "was", "no", "familial", "history", "of", "cancer.", "Individuals", "III-3", "and", "III-4", "inherited", "also", "the", "deleterious", "variant.", "No", "genetic", "testing", "was", "available", "from", "the", "father", "or", "paternal", "relatives", "(Family", "#2,", "Figure", "3)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In the second LS family, the index subject, one sister and one brother with CRC (II-5; II-6; II-7, respectively) had a deleterious variant in MSH6 (c.3013C>T; p.Arg1005X) but did not have the p.Lys618Ala variant. This variant was present in only three of four unaffected nephews (III-2; III-3; III-4) and was inherited from the parental branch, in which there was no familial history of cancer. Individuals III-3 and III-4 inherited also the deleterious variant. No genetic testing was available from the father or paternal relatives (Family #2, Figure 3).
3034663-05-Discussion-p01
[ "The", "results", "of", "in", "silico", "prediction", "and", "functional", "assays", "alone", "are", "insufficient", "to", "determine", "whether", "this", "variant", "is", "deleterious", "or", "a", "rare", "functional", "polymorphism.", "For", "this", "purpose,", "it", "is", "necessary", "to", "integrate", "indirect", "evidence", "with", "direct", "genetic", "evidence", "involving", "clinical", "observations", "of", "disease", "occurrence." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The results of in silico prediction and functional assays alone are insufficient to determine whether this variant is deleterious or a rare functional polymorphism. For this purpose, it is necessary to integrate indirect evidence with direct genetic evidence involving clinical observations of disease occurrence.
1266026-05-Discussion-p01
[ "An", "epigenetic", "mechanism", "may", "help", "explain", "why", "sporadic", "MSI+", "cancers", "require", "more", "than", "one", "additional", "somatic", "alteration", "relative", "to", "HNPCC", "cancers.", "Inactivation", "of", "the", "normal", "MMR", "allele", "occurs", "through", "mutation", "(usually", "LOH", "[15])", "in", "HNPCC", "whereas", "MMR", "loss", "in", "sporadic", "MSI+", "cancers", "is", "associated", "with", "MLH1", "promoter", "methylation", "[16,17].", "CpG", "islands", "may", "be", "\"protected\"", "from", "methylation", "because", "most", "are", "unmethylated", "at", "birth", "and", "usually", "remain", "unmethylated", "throughout", "life", "[18].", "Epigenetic", "MLH1", "inactivation", "may", "require", "at", "least", "two", "cis", "acting", "somatic", "alterations---loss", "of", "a", "mechanism", "that", "normally", "prevents", "methylation,", "followed", "by", "the", "accumulation", "of", "methylation", "at", "sufficient", "numbers", "of", "CpG", "sites", "to", "silence", "expression." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
An epigenetic mechanism may help explain why sporadic MSI+ cancers require more than one additional somatic alteration relative to HNPCC cancers. Inactivation of the normal MMR allele occurs through mutation (usually LOH [15]) in HNPCC whereas MMR loss in sporadic MSI+ cancers is associated with MLH1 promoter methylation [16,17]. CpG islands may be "protected" from methylation because most are unmethylated at birth and usually remain unmethylated throughout life [18]. Epigenetic MLH1 inactivation may require at least two cis acting somatic alterations---loss of a mechanism that normally prevents methylation, followed by the accumulation of methylation at sufficient numbers of CpG sites to silence expression.
1334229-02-Background-p01
[ "Genetic", "instability", "is", "seen", "in", "most", "types", "of", "cancer", "[10].", "Two", "distinct", "types", "of", "genetic", "instability", "appear", "to", "occur", "in", "colorectal", "cancer", "[11]:", "chromosomal", "and", "microsatellite", "instability.", "Chromosomal", "instability", "results", "in", "gains", "or", "losses", "of", "entire", "chromosomes", "or", "parts", "of", "them,", "and", "gives", "rise", "to", "aneuploid", "tumours", "and", "occurs", "in", "the", "majority", "of", "cancers.", "A", "smaller", "proportion", "of", "colorectal", "cancers", "displays", "microsatellite", "instability,", "represented", "by", "diploid", "cells", "acquiring", "high", "mutation", "rates,", "and", "was", "found", "to", "be", "associated", "with", "defective", "mismatch", "repair", "[12].", "These", "tumours", "are", "less", "likely", "to", "harbour", "mutations", "in", "genes", "associated", "with", "chromosomally", "instable", "and", "generally", "aneuploid", "tumours,", "such", "as", "APC,", "K-ras", "and", "TP53", "[13-21],", "suggesting", "that", "these", "tumours", "form", "a", "distinct", "group.", "Moreover,", "microsatellite", "instable", "tumours", "are", "found", "predominantly", "in", "the", "proximal", "colon", "[22,23],", "are", "more", "likely", "to", "occur", "in", "patients", "with", "a", "positive", "family", "history", "of", "colorectal", "cancer", "[22,23],", "are", "often", "less", "differentiated", "than", "microsatellite", "stable", "tumours", "[22],", "and", "occur", "more", "frequently", "in", "women", "[24]", "and", "at", "older", "age", "[25].", "Moreover,", "in", "tumours", "displaying", "microsatellite", "instability,", "mutations", "the", "CTNNB1", "gene", "were", "more", "frequent", "[26]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Genetic instability is seen in most types of cancer [10]. Two distinct types of genetic instability appear to occur in colorectal cancer [11]: chromosomal and microsatellite instability. Chromosomal instability results in gains or losses of entire chromosomes or parts of them, and gives rise to aneuploid tumours and occurs in the majority of cancers. A smaller proportion of colorectal cancers displays microsatellite instability, represented by diploid cells acquiring high mutation rates, and was found to be associated with defective mismatch repair [12]. These tumours are less likely to harbour mutations in genes associated with chromosomally instable and generally aneuploid tumours, such as APC, K-ras and TP53 [13-21], suggesting that these tumours form a distinct group. Moreover, microsatellite instable tumours are found predominantly in the proximal colon [22,23], are more likely to occur in patients with a positive family history of colorectal cancer [22,23], are often less differentiated than microsatellite stable tumours [22], and occur more frequently in women [24] and at older age [25]. Moreover, in tumours displaying microsatellite instability, mutations the CTNNB1 gene were more frequent [26].
1373649-02-Background-p01
[ "This", "autosomal", "dominantly", "inherited", "disorder", "is", "caused", "by", "germline", "mutations", "in", "genes", "coding", "proteins", "responsible", "for", "the", "repair", "of", "DNA", "replication", "errors,", "which", "are", "referred", "to", "as", "DNA", "mismatch", "repair", "(MMR)", "genes", "[5].", "DNA", "mismatch", "repair", "machinery", "plays", "a", "critical", "role", "in", "genomic", "stability,", "including", "correction", "of", "mispaired", "bases", "associated", "with", "DNA", "replication", "and", "recombination.", "Germline", "mutations", "in", "one", "allele", "of", "any", "of", "these", "genes", "followed", "by", "the", "somatic", "loss", "or", "inactivation", "of", "the", "wild-type", "allele", "leads", "to", "a", "defective", "mismatch", "repair", "mechanism.", "The", "current", "\"gold", "standard\"", "for", "assessing", "tumor", "DNA", "MMR", "activity", "is", "molecular", "microsatellite", "instability", "(MSI)", "testing.", "In", "most", "cases,", "it", "involves", "extracting", "DNA", "from", "both", "tumor", "and", "normal", "tissue.", "The", "DNA", "is", "subjected", "to", "polymerase", "chain", "reaction", "(PCR)", "amplification", "of", "five", "or", "more", "different", "chromosomal", "loci", "that", "compare", "\"microsatellites\",", "running", "the", "PCR", "products", "through", "a", "gel", "to", "separate", "DNA", "fragments", "by", "size,", "comparing", "the", "tumor-normal", "pairs,", "and", "scoring", "for", "differences", "between", "the", "two.", "Instability", "at", "two", "or", "more", "out", "of", "five", "markers", "defines", "a", "tumor", "Colorectal", " ", "cancer", "affecting", "at", "least", "2", "successive", "generations;", "and", "3.", "At", "least", "one", "relative", "diagnosed", "with", "colorectal", "cancer", "under", "the", "age", "of", "50", ".", "The", "fulfillment", "of", "these", "criteria", "prompted", "further", "genetics", "investigations.", "More", "recently", "it", "has", "been", "revised", "to", "take", "into", "account", "the", "prevalence", "of", "extracolonic", "cancer", "in", "certain", "HNPCC", "families", "[4]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 15, 16, 16, 16, 16, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
This autosomal dominantly inherited disorder is caused by germline mutations in genes coding proteins responsible for the repair of DNA replication errors, which are referred to as DNA mismatch repair (MMR) genes [5]. DNA mismatch repair machinery plays a critical role in genomic stability, including correction of mispaired bases associated with DNA replication and recombination. Germline mutations in one allele of any of these genes followed by the somatic loss or inactivation of the wild-type allele leads to a defective mismatch repair mechanism. The current "gold standard" for assessing tumor DNA MMR activity is molecular microsatellite instability (MSI) testing. In most cases, it involves extracting DNA from both tumor and normal tissue. The DNA is subjected to polymerase chain reaction (PCR) amplification of five or more different chromosomal loci that compare "microsatellites", running the PCR products through a gel to separate DNA fragments by size, comparing the tumor-normal pairs, and scoring for differences between the two. Instability at two or more out of five markers defines a tumor Colorectal cancer affecting at least 2 successive generations; and 3. At least one relative diagnosed with colorectal cancer under the age of 50 . The fulfillment of these criteria prompted further genetics investigations. More recently it has been revised to take into account the prevalence of extracolonic cancer in certain HNPCC families [4].
1557864-05-Discussion-p01
[ "Next", "we", "studied", "the", "association", "between", "MMR", "inactivation", "and", "cisplatin", "resistance", "in", "these", "cell", "lines.", "MMR", "inactivation", "seen", "in", "SKOV3", "and", "2774", "might", "result", "in", "the", "relative", "resistance", "to", "cisplatin", "compared", "to", "the", "other", "cell", "lines.", "On", "the", "other", "hand,", "A2780", "which", "has", "clearly", "an", "inactive", "MMR", "MMR", " ", "inactivation", "and", "cisplatin", "resistance", "in", "these", "cell", "lines.", "MMR", "inactivation", "cell", "lines", " ", "analyzed", "by", "us." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 17, 18, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 19, 20, 9, 10, 0, 0, 0, 0 ]
Next we studied the association between MMR inactivation and cisplatin resistance in these cell lines. MMR inactivation seen in SKOV3 and 2774 might result in the relative resistance to cisplatin compared to the other cell lines. On the other hand, A2780 which has clearly an inactive MMR MMR inactivation and cisplatin resistance in these cell lines. MMR inactivation cell lines analyzed by us.
1619718-04-Results-p03
[ "Aberrant", "expression", "of", "p53", "and", "correlation", "with", "MGMT", "loss" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Aberrant expression of p53 and correlation with MGMT loss
1334229-05-Discussion-p02
[ "The", "method", "for", "mutation", "analysis", "of", "the", "APC", "mutation", "cluster", "region", "and", "exon", "1", "of", "K-ras", "is", "based", "on", "nested", "amplification", "and", "direct", "sequencing", "of", "purified", "PCR", "fragments,", "a", "highly", "sensitive", "method.", "Since", "no", "screening", "step", "was", "performed", "prior", "to", "the", "sequencing", "of", "the", "gene", "fragments,", "it", "is", "unlikely", "that", "mutations", "would", "have", "escaped", "detection.", "The", "reproducibility", "of", "the", "applied", "assays", "was", "good,", "with", "a", "reproducibility", "of", "85%", "and", "88%", "for", "APC", "and", "K-ras,", "respectively.", "Arguably,", "this", "indicates", "the", "extent", "of", "heterogeneity", "present", "in", "the", "tumour", "samples." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The method for mutation analysis of the APC mutation cluster region and exon 1 of K-ras is based on nested amplification and direct sequencing of purified PCR fragments, a highly sensitive method. Since no screening step was performed prior to the sequencing of the gene fragments, it is unlikely that mutations would have escaped detection. The reproducibility of the applied assays was good, with a reproducibility of 85% and 88% for APC and K-ras, respectively. Arguably, this indicates the extent of heterogeneity present in the tumour samples.
1373649-04-Results-and-discussion-p01
[ "Three", "out", "of", "five", "microsatellite", "markers", "(BAT-25,", "BAT-26", "and", "D5S346)", "presented", "alleles", "in", "the", "proband's", "primary", "tumor", "(T')", "and", "its", "metastasis", "(T\")", "different", "from", "those", "inherited", "from", "his", "parents.", "This", "observation", "suggested", "a", "dysfunction", "of", "the", "mismatch", "repair", "system", "and", "the", "tumor", "was", "classified", "as", "high", "frequency", "MSI", "(MSI-H)", "according", "to", "the", "NCI", "workshop", "[12].", "Direct", "sequencing", "of", "the", "hMSH2", "and", "hMLH1", "genes", "was", "indicated,", "detecting", "a", "novel", "germline", "mutation,", "a", "c.1864C>A", "transversion", "in", "exon", "12", "of", "hMSH2", "gene", "at", "the", "heterozygous", "state", "(fig.", "3)", "leading", "to", "a", "proline", "622", "to", "threonine", "(p.Pro622Thr)", "amino", "acid", "substitution.", "This", "is", "the", "second", "report", "involving", "the", "622", "codon", "in", "HNPCC", "[13]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Three out of five microsatellite markers (BAT-25, BAT-26 and D5S346) presented alleles in the proband's primary tumor (T') and its metastasis (T") different from those inherited from his parents. This observation suggested a dysfunction of the mismatch repair system and the tumor was classified as high frequency MSI (MSI-H) according to the NCI workshop [12]. Direct sequencing of the hMSH2 and hMLH1 genes was indicated, detecting a novel germline mutation, a c.1864C>A transversion in exon 12 of hMSH2 gene at the heterozygous state (fig. 3) leading to a proline 622 to threonine (p.Pro622Thr) amino acid substitution. This is the second report involving the 622 codon in HNPCC [13].
2275286-04-Results-p02
[ "*Amsterdam", "criteria", "II" ]
[ 0, 0, 0 ]
*Amsterdam criteria II
1557864-01-Abstract-p01
[ "Methods" ]
[ 0 ]
Methods
1601966-06-Methods-p01
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1334229-01-Abstract-p01
[ "Mutations", "at", "the", "phosphorylation", "sites", "(codons", "31,", "33,", "37,", "and", "45)", "in", "the", "CTNNB1", "gene", "were", "observed", "in", "tumours", "from", "only", "5/464", "patients.", "Tumours", "with", "truncating", "APC", "mutations", "and", "activating", "K-ras", "mutations", "in", "codons", "12", "and", "13", "occurred", "at", "similar", "frequencies", "(37%", "(245/656)", "and", "36%", "(", "235/656", "hMLH1", " ", "in", "sporadic", "colorectal", "carcinomas", "from", "the", "Netherlands", "Cohort", "Study" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutations at the phosphorylation sites (codons 31, 33, 37, and 45) in the CTNNB1 gene were observed in tumours from only 5/464 patients. Tumours with truncating APC mutations and activating K-ras mutations in codons 12 and 13 occurred at similar frequencies (37% (245/656) and 36% ( 235/656 hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study
1266026-04-Results-p01
[ "Duke's", "stage", "and", "age", "at", "clinical", "presentation", "(Figure", "1B)", "were", "documented", "for", "884", "of", "the", "895", "MSI-", "sporadic", "cancers", "(Table", "1).", "Average", "ages", "were", "68.6", "years", "for", "stage", "A,", "69.0", "years", "for", "stage", "B,", "65.2", "years", "for", "stage", "C,", "and", "65.4", "years", "for", "stage", "D.", "The", "most", "likely", "numbers", "of", "oncogenic", "mutations", "were", "seven", "for", "stage", "A", "cancers,", "eight", "for", "stage", "B", "cancers,", "and", "six", "for", "stage", "C", "or", "D", "cancers", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Duke's stage and age at clinical presentation (Figure 1B) were documented for 884 of the 895 MSI- sporadic cancers (Table 1). Average ages were 68.6 years for stage A, 69.0 years for stage B, 65.2 years for stage C, and 65.4 years for stage D. The most likely numbers of oncogenic mutations were seven for stage A cancers, eight for stage B cancers, and six for stage C or D cancers (Table 1).
1373649-02-Background-p01
[ "We", "describe", "MSI", "testing", "in", "the", "absence", "of", "proband", "non-tumor", "tissue", "using", "the", "Bethesda", "consensus", "panel", "(mononucleotide", "repeats", "BAT25", "and", "BAT26,", "and", "dinucleotide", "repeats", "D2S123,", "D5S346,", "and", "D17S250)", "and", "we", "report", "a", "novel", "hMSH2", "germline", "mutation", "hMLH1", "hMLH1", ",", "hPMS1,", "hPMS2,", "hMSH3,", "and", "hMSH6.", "Most", "of", "the", "HNPCC", "families", "in", "which", "mutations", "have", "been", "identified", "involved", "hMSH2", "and", "hMLH1", "genes", "[6]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 21, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
We describe MSI testing in the absence of proband non-tumor tissue using the Bethesda consensus panel (mononucleotide repeats BAT25 and BAT26, and dinucleotide repeats D2S123, D5S346, and D17S250) and we report a novel hMSH2 germline mutation hMLH1 hMLH1 , hPMS1, hPMS2, hMSH3, and hMSH6. Most of the HNPCC families in which mutations have been identified involved hMSH2 and hMLH1 genes [6].
1557864-01-Abstract-p01
[ "Methods" ]
[ 0 ]
Methods
1619718-04-Results-p01
[ "SSAs", "were", "more", "likely", "to", "have", "BRAF", "mutation", "(81%)", "than", "either", "SAs", "(33%)", "(P", "<", "0.001)", "or", "MPs", "(40%)", "(P", "<", "0.02).", "KRAS", "mutation", "was", "infrequent", "among", "both", "SSAs", "(3%)", "and", "HPs", "(4%)", "(Table", "1).", "Patient", "age,", "gender", "and", "anatomical", "location", "were", "not", "predictors", "of", "BRAF", "mutation", "in", "either", "SSAs", "or", "HPs.", "The", "mean", "age", "of", "subjects", "with", "SSAs", "(64", "years)", "differed", "from", "that", "of", "subjects", "with", "HPs", "(55", "years)", "(P", "<", "0.001)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
SSAs were more likely to have BRAF mutation (81%) than either SAs (33%) (P < 0.001) or MPs (40%) (P < 0.02). KRAS mutation was infrequent among both SSAs (3%) and HPs (4%) (Table 1). Patient age, gender and anatomical location were not predictors of BRAF mutation in either SSAs or HPs. The mean age of subjects with SSAs (64 years) differed from that of subjects with HPs (55 years) (P < 0.001).